CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10143929,101439295,5,F,,20150501,20140430,20150515,EXP,,CA-009507513-1007USA00479,MERCK,,54,YR,,M,Y,,,20150515,N,OT,US,CA,SUSTIVA,Depression;Drug interaction,101439295,OT,,,,,,,,,101439295,1,Product used for unknown indication
10202591,102025912,2,F,,20150421,20140528,20150501,EXP,,GB-GILEAD-2014-0103166,GILEAD,,,,,M,Y,,,20150501,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Congenital anomaly;Twin reversed arterial perfusion sequence malformation,102025912,CA,,,102025912,1,20131105,20140123,,,102025912,1,HIV infection
10292565,102925654,4,F,2013,20150519,20140710,20150527,EXP,,CH-GILEAD-2014-0106572,GILEAD,"WAGNER N, WYLER-LAZAREVIC CA, YERLY S, SAMER C, PEYTAVIN G, POSFAY-BARBE KM, CALMY A, AMBROSIONI J. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN A SEVERELY OVERWEIGHT CHILD WITH A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION. A CASE REPORT AND REVIEW. NEW MICROBES AND NEW INFECTIONS. 2015;6:1-4",11,YR,C,M,Y,56.5,KG,20150527,N,OT,CH,CH,EFAVIRENZ,Drug ineffective,102925654,OT,,,102925654,1,201305,,,,102925654,1,HIV infection
10377280,103772803,3,F,20060512,20150608,20140812,20150622,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14021034,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20150622,N,CN,JP,JP,EFAVIRENZ,Blood glucose increased;Hypercholesterolaemia;Nephrolithiasis,103772803,HO,,,103772803,1,20060125,20120523,,,103772803,1,HIV infection
10471306,104713062,2,F,20140721,20150402,20140923,20150408,EXP,,MW-009507513-1409MWI010789,MERCK,,35,YR,,M,Y,,,20150408,N,CN,US,MW,EFAVIRENZ,Pleural effusion;Pneumonia,104713062,OT,,,104713062,1,20140717,20141009,,,104713062,1,HIV infection
10475669,104756692,2,F,20140825,20150611,20140925,20150617,EXP,,BW-ABBVIE-14P-019-1285352-00,ABBVIE,,32,YR,,F,Y,,,20150617,N,MD,COUNTRY NOT SPECIFIED,BW,EFAVIRENZ,Abortion spontaneous,104756692,OT,,,104756692,1,20140806,20140806,,,104756692,1,HIV infection
10525523,105255232,2,F,20140902,20150602,20141017,20150604,EXP,,UG-GILEAD-2014-0118171,GILEAD,,20,YR,A,M,Y,,,20150604,N,MD,UG,UG,EFAVIRENZ,Bladder outlet obstruction;Gastritis;Glomerulonephritis,105255232,LT,,,105255232,1,20140811,20140909,,,105255232,1,HIV infection
10529194,105291945,5,F,201409,20150421,20141020,20150626,EXP,FR-ANSM-PV20140326,FR-GILEAD-2014-0118805,GILEAD,,58,YR,A,M,Y,74,KG,20150626,N,OT,FR,FR,EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE/EFAVIRENZ,Bradycardia;Bundle branch block;Syncope,105291945,LT,,,105291945,1,20140829,201502,,,105291945,1,Hepatitis C
10540677,105406773,3,F,20140929,20150430,20141022,20150512,EXP,,MW2014GSK005599,VIIV,,12,YR,,F,N,15.0,KG,20150508,N,MD,MW,,EFAVIRENZ,Anaemia;Malnutrition;Pulmonary tuberculosis,105406773,OT,105406773,FGN,105406773,1,20140214,,,,105406773,1,HIV infection
10551960,105519602,2,F,,20150505,20141029,20150513,EXP,,US-PFIZER INC-2014293808,PFIZER,,53,YR,,F,Y,,,20150513,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105519602,OT,,,105519602,2,20131028,20140410,,,105519602,1,HIV infection
10557837,105578373,3,F,201402,20150505,20141031,20150512,EXP,,US-ABBVIE-14P-163-1299475-00,ABBVIE,,53,YR,,F,Y,,,20150512,N,OT,US,US,EFAVIRENZ,Drug ineffective;Gene mutation;Multiple-drug resistance;Pathogen resistance,105578373,OT,,,105578373,2,20131028,20140410,,,105578373,1,HIV infection
10560768,105607682,2,F,,20150505,20141103,20150512,EXP,,US-GLAXOSMITHKLINE-US2014GSK014223,GLAXOSMITHKLINE,,53,YR,,F,Y,,,20150512,N,CN,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105607682,OT,,,105607682,1,1996,20140410,,,105607682,1,HIV infection
10566372,105663723,3,F,,20150505,20141105,20150518,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-21532072,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150518,N,CN,US,US,EFAVIRENZ,Drug dose omission;Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105663723,OT,,,105663723,1,1996,,,,105663723,1,HIV infection
10568009,105680092,2,F,,20150505,20141104,20150514,EXP,,US2014GSK014223,VIIV,,53,YR,,F,N,,,20150512,N,OT,US,,EFAVIRENZ (EFAVIRENZ),Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105680092,OT,105680092,HP,105680092,1,20131028,20140410,,,105680092,1,HIV infection
10568506,105685063,3,F,,20150505,20141106,20150520,EXP,,US-009507513-1411USA002189,MERCK,,53,YR,,F,Y,,,20150520,N,CN,US,US,EFAVIRENZ,Drug dose omission;Drug ineffective;Multiple-drug resistance;Viral mutation identified;Virologic failure,105685063,OT,,,105685063,1,1996,20140410,,,105685063,1,HIV infection
10584543,105845434,4,F,20140719,20150331,20141114,20150408,EXP,,IT-MERCK-1411ITA005148,MERCK,,51,YR,,M,Y,76,KG,20150408,N,CN,IT,IT,SUSTIVA,Abdominal pain;Back pain;Myalgia,105845434,DE,,,105845434,1,20140401,20140805,,,105845434,1,Hypercholesterolaemia
10675079,106750798,8,F,20140207,20150617,20141224,20150630,EXP,,PE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-000825,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,52,KG,20150630,N,CN,PE,PE,EFAVIRENZ,Anaemia;Colon cancer;Haematochezia;Leukaemia;Multi-organ failure;Non-Hodgkin's lymphoma;Proctalgia;Sepsis;Syphilis,106750798,DE,,,106750798,1,20140131,20141114,,,106750798,1,HIV infection
10733173,107331734,4,F,20140823,20150518,20150120,20150528,EXP,,B1006356A,VIIV,,,,,M,N,,,20150526,N,CN,RU,,EFAVIRENZ,Asthenia;Chronic gastritis;Duodenitis;Erosive oesophagitis;Fungal test positive;Gastric disorder;Gastric polyps;Gastritis;Gastritis haemorrhagic;Gastrooesophageal reflux disease;Head discomfort;Hiatus hernia;Hyperchlorhydria;Influenza like illness;Initial insomnia;Lymph node pain;Musculoskeletal discomfort;Nail discolouration;Nasal obstruction;Nasopharyngitis;Nervousness;Neurosis;Oropharyngeal pain;Pharyngeal disorder;Pharyngeal erosion;Pharyngeal erythema;Pharyngeal mucosa atrophy;Pneumonia streptococcal;Pyrexia;Respiratory tract infection viral;Rhinorrhoea;Tongue coated;Tonsillar inflammation,107331734,OT,107331734,CSM,107331734,1,201312,,,,107331734,1,HIV infection
10770830,107708303,3,F,20141024,20150611,20150206,20150617,EXP,,MW-ABBVIE-15P-100-1341646-00,ABBVIE,,25,YR,,F,Y,,,20150617,N,MD,COUNTRY NOT SPECIFIED,MW,SUSTIVA,Abortion spontaneous,107708303,OT,,,107708303,1,20141024,20150121,,,107708303,1,HIV infection
10796648,107966482,2,F,,20150518,20150216,20150526,EXP,,US-AMGEN-USASP2015012469,AMGEN,"M KOWALCZYK, P G RUBINSTEIN, D M ABOULAFIA, ET AL.. INITIAL EXPERIENCE WITH THE USE OF THROMBOPOETIN RECEPTOR AGONISTS IN PATIENTS WITH REFRACTORY HIV-ASSOCIATED IMMUNE THROMBOCYTOPENIC PURPURA. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2015;14 (3):211-216",43,YR,A,F,Y,,,20150525,N,MD,US,US,EFAVIRENZ,Chest pain;Coronary artery stenosis;Electrocardiogram ST segment elevation;Myocardial infarction;Myocardial necrosis marker increased;Therapeutic response decreased,107966482,OT,,,,,,,,,107966482,1,Immune thrombocytopenic purpura
10867262,108672622,2,F,20150115,20150519,20150225,20150601,EXP,,FR-CELGENE-FRA-2015023006,CELGENE,,66,YR,,M,Y,,,20150601,N,OT,FR,FR,Efavirenz,Anaemia;Blindness;Neutropenia;Retinal vascular occlusion;Vision blurred;Visual acuity reduced,108672622,OT,,,108672622,1,20150114,20150115,,,108672622,1,Plasma cell myeloma
10902829,109028292,2,F,20150208,20150520,20150310,20150528,EXP,,US-GILEAD-2015-0140381,GILEAD,,50,YR,A,F,Y,80.3,KG,20150528,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Overdose;Suicide attempt,109028292,OT,,,109028292,1,20111216,,,,109028292,1,HIV infection
10917808,109178082,2,F,20150126,20150413,20150316,20150420,EXP,,CO-GLAXOSMITHKLINE-CO2015GSK033251,GLAXOSMITHKLINE,,30,YR,,M,Y,70,KG,20150420,N,CN,CO,CO,EFAVIRENZ,Hypersensitivity;Urticaria,109178082,OT,,,109178082,1,20150126,20150210,,,109178082,1,HIV test positive
10925977,109259773,3,F,,20150327,20150318,20150402,EXP,,ES-GLAXOSMITHKLINE-ES2015GSK032181,GLAXOSMITHKLINE,,45,YR,,F,Y,,,20150402,N,MD,ES,ES,Efavirenz,Angina pectoris,109259773,OT,,,109259773,1,20140813,,,,109259773,1,HIV infection
10926025,109260252,2,F,20141229,20150626,20150318,20150630,EXP,,ID-009507513-1502IDN010580,MERCK,,34,YR,,M,Y,,,20150630,N,CN,US,ID,EFAVIRENZ,Autoimmune hepatitis;Cholangitis sclerosing,109260252,HO,,,109260252,1,20141103,20141229,,,109260252,1,Hepatitis C
10926507,109265072,2,F,20141201,20150331,20150318,20150409,EXP,,ZA-GILEAD-2015-0141781,GILEAD,,28,YR,A,F,Y,61.6,KG,20150409,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Ruptured ectopic pregnancy,109265072,OT,,,109265072,1,20140324,,,,109265072,1,HIV infection
10929964,109299642,2,F,,20150330,20150317,20150410,EXP,,2015HINOTH0256,HETERO,,,,,F,N,,,20150408,N,OT,US,,EFAVIRENZ (EFAVIRENZ),Congenital acrochordon;Maternal drugs affecting foetus;Polydactyly,109299642,OT,109299642,HP,109299642,1,2009,,,,109299642,1,Antiviral treatment
10931227,109312272,2,F,20150126,20150413,20150317,20150421,EXP,,CO2015GSK033251,VIIV,,30,YR,,M,N,70,KG,20150419,N,PH,CO,,EFAVIRENZ (EFAVIRENZ),Hypersensitivity;Urticaria,109312272,RI,109312272,HP,109312272,1,20150126,20150210,,,109312272,1,HIV test positive
10949295,109492952,2,F,,20150327,20150320,20150406,EXP,,ES2015GSK032181,VIIV,,45,YR,,F,N,,,20150402,N,MD,ES,,EFAVIRENZ (EFAVIRENZ),Angina pectoris,109492952,RI,109492952,FGN,109492952,1,20140813,,,,109492952,1,HIV infection
10960639,109606392,2,F,,20150518,20150325,20150528,EXP,,B1027202A,VIIV,,,,,M,N,,,20150522,N,CN,UZ,,EFAVIRENZ (EFAVIRENZ),Anxiety;Arthralgia;Conversion disorder;Depression;Diarrhoea;Disturbance in attention;Fear of death;Impaired work ability;Irritability;Neck pain;Poisoning;Renal disorder;Weight decreased,109606392,HO,109606392,FGN,,,,,,,109606392,1,HIV infection
10965025,109650252,2,F,,20150331,20150330,20150406,EXP,,IN-AUROBINDO-AUR-APL-2015-02603,AUROBINDO,,27,YR,,M,Y,,,20150404,N,MD,IN,IN,Efavirenz,Acid fast bacilli infection;Arthralgia;Cellulitis;Dactylitis;Decreased appetite;Deformity;Disseminated tuberculosis;Dyspnoea;Hypokinesia;Immune reconstitution inflammatory syndrome associated tuberculosis;Joint warmth;Osteomyelitis acute;Pain;Pneumonia klebsiella;Pyrexia;Sepsis;Swelling;Tachycardia;Tenderness;Toxicity to various agents;Ulcer;Ulcer haemorrhage,109650252,OT,,,109650252,1,20101222,,,,109650252,1,HIV infection
10966389,109663892,2,F,20150310,20150414,20150330,20150427,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-018204,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,70,KG,20150427,N,CN,MW,MW,EFAVIRENZ,Disseminated tuberculosis;Haemoglobin decreased;Non-Hodgkin's lymphoma,109663892,OT,,,109663892,1,20140515,20150309,,,109663892,1,HIV infection
10968451,109684513,3,F,20150129,20150325,20150330,20150407,EXP,,KE-009507513-1502GBR008935,MERCK,,38,YR,,F,Y,52.3,KG,20150407,N,MD,KE,KE,EFAVIRENZ,Death;Muscular weakness;Tuberculosis,109684513,OT,,,109684513,1,20141001,20141217,,,109684513,1,HIV infection
10970781,109707812,2,F,20140621,20150513,20150331,20150521,EXP,,FR-PURDUE PHARMA-GBR-2015-0026584,PURDUE,,48,YR,,M,Y,,,20150521,N,OT,FR,FR,SUSTIVA,Aortic bypass;Drug abuse;Intentional product misuse;Peripheral artery thrombosis,109707812,OT,,,109707812,1,20140627,20140630,,,109707812,1,Product used for unknown indication
10975184,109751842,2,F,20141008,20150605,20150401,20150610,EXP,,KE-GILEAD-2015-0145425,GILEAD,,30,YR,A,M,Y,51.6,KG,20150610,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Anaemia;Hyponatraemia,109751842,OT,,,109751842,1,20140821,20141008,,,109751842,1,HIV infection
10975394,109753941,1,I,200905,20150323,20150401,20150401,EXP,,BR-GLAXOSMITHKLINE-BR2015GSK043089,GLAXOSMITHKLINE,"GOIS L, BADARO R, SCHOOLEY R AND GRASSI M.F.R. IMMUNE RESPONSE TO LEISHMANIA ANTIGENS IN AN AIDS PATIENT WITH MUCOCUTANEOUS LEISHMANIASIS AS A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS): A CASE REPORT. BMC INFECTIOUS DISEASES. 2015;15:58",29,YR,,M,Y,,,20150401,N,OT,BR,BR,Efavirenz,Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mucocutaneous leishmaniasis;Myiasis;Nasal obstruction;Skin necrosis;Skin ulcer;Swelling,109753941,OT,,,109753941,1,200812,,,,109753941,1,HIV infection
10975968,109759681,1,I,200209,20150320,20150401,20150401,EXP,,HR-MYLANLABS-2015M1010534,MYLAN,"VISKOVIC K, STEMBERGER L, BRNIC Z, BEGOVAC J. REPEATED PRESENTATION OF GRAVES^S DISEASE AS A MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN AN HIV-INFECTED PATIENT TAKING HAART: CASE REPORT. ACTA-CLIN-CROAT 2013; 52(1):125-127.",,,,,Y,,,20150401,N,MD,HR,HR,EFAVIRENZ,Basedow's disease;Immune reconstitution inflammatory syndrome,109759681,OT,,,109759681,1,200101,,,,109759681,1,HIV infection
10978129,109781291,1,I,,20150322,20150402,20150402,EXP,,IN-CIPLA LTD.-2015IN02573,CIPLA,"RAMESH R. ALLAMA, MANOJ V. MURHEKARA, TARUN BHATNAGARA, CHENGAPPA K. UTHAPPAB, C. NALINIB, B. B. REWARIC AND SANJAY M MEHENDALEA. PREDICTORS OF IMMUNOLOGICAL FAILURE AND DETERMINANTS OF SUBOPTIMAL CD4 TESTING AMONG ADULTS WITH HIV ON FIRST-LINE ANTIRETROVIRAL THERAPY IN ANDHRA PRADESH, INDIA, 2008?2011. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2015;1 TO 9",,,,,Y,,,20150402,N,OT,IN,IN,Efavirenz,Death,109781291,DE,,,,,,,,,109781291,1,HIV infection
10978477,109784772,2,F,20150112,20150403,20150402,20150417,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019001,BRISTOL MYERS SQUIBB,,12,YR,,M,Y,,,20150417,N,CN,US,KE,EFAVIRENZ,Gastroenteritis,109784772,HO,,,,,,,,,109784772,1,Antiretroviral therapy
10980384,109803842,2,F,20150131,20150413,20150402,20150422,EXP,,KE-GILEAD-2015-0145809,GILEAD,,38,YR,A,F,Y,,,20150422,N,MD,KE,KE,EFAVIRENZ,Death;Muscular weakness;Pyelonephritis;Tuberculosis,109803842,HO,,,109803842,1,20141001,20150323,,,109803842,1,HIV infection
10981008,109810081,1,I,200011,20150325,20150402,20150402,EXP,,"US-ROXANE LABORATORIES, INC.-2015-BI-16629GD",ROXANE,"RAZONABLE R,AKSAMIT A,WRIGHT A,WILSON J. CIDOFOVIR TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. MAYO CLIN PROC 2001 NOV;76:11:1171-1175.",55,YR,,M,Y,,,20150403,N,OT,COUNTRY NOT SPECIFIED,US,EFAVIRENZ,Immune system disorder;Progressive multifocal leukoencephalopathy,109810081,OT,,,109810081,1,200009,200009,,,109810081,1,Acquired immunodeficiency syndrome
10982690,109826901,1,I,,20150322,20150403,20150403,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019405,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150403,N,CN,ES,ES,EFAVIRENZ,Congenital hydronephrosis;Foetal exposure during pregnancy,109826901,CA,,,,,,,,,109826901,1,Product used for unknown indication
10982711,109827111,1,I,,20150322,20150403,20150403,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-021660,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150403,N,CN,ES,ES,EFAVIRENZ,Congenital hydronephrosis;Foetal exposure during pregnancy,109827111,CA,,,,,,,,,109827111,1,Product used for unknown indication
10982726,109827261,1,I,,20150322,20150403,20150403,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-021661,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150403,N,CN,ES,ES,EFAVIRENZ,Congenital anomaly;Foetal exposure during pregnancy,109827261,CA,,,,,,,,,109827261,1,Product used for unknown indication
10983607,109836071,1,I,,20150325,20150403,20150403,EXP,,US-GILEAD-2015-0145197,GILEAD,,61,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthma;Blood creatinine increased;CD4 lymphocytes decreased;Diabetes mellitus;Drug ineffective;Drug resistance;Glomerular filtration rate decreased;Hyperlipidaemia;Renal failure;Treatment noncompliance,109836071,OT,,,109836071,1,201402,,,,109836071,1,Product used for unknown indication
10983647,109836471,1,I,2015,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145237,GILEAD,,45,YR,A,F,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;CD4 lymphocytes abnormal;Diabetes mellitus;Drug ineffective;Drug resistance;HIV test positive;Hyperlipidaemia;Treatment noncompliance;Virologic failure,109836471,OT,,,109836471,1,201501,,,,109836471,1,HIV infection
10983854,109838541,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145308,GILEAD,,31,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthma;CD4 lymphocytes abnormal;Diabetes mellitus;Drug ineffective;HIV test positive;Hypertension;Treatment noncompliance;Virologic failure,109838541,OT,,,109838541,1,201411,,,,109838541,1,Product used for unknown indication
10983865,109838651,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145360,GILEAD,,30,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Drug ineffective;Drug resistance;Gastrooesophageal reflux disease,109838651,OT,,,,,,,,,109838651,1,Product used for unknown indication
10984026,109840261,1,I,,20150325,20150403,20150403,EXP,,US-GILEAD-2015-0145449,GILEAD,,49,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Diabetes mellitus;Drug ineffective;Drug resistance;Hyperlipidaemia;Hypertension;Treatment noncompliance,109840261,OT,,,109840261,1,200911,,,,109840261,1,Product used for unknown indication
10984051,109840511,1,I,2015,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145925,GILEAD,,30,YR,A,F,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Drug ineffective;Renal failure;Treatment noncompliance;Viral load increased,109840511,OT,,,109840511,1,201501,,,,109840511,1,Product used for unknown indication
10984115,109841151,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145949,GILEAD,,45,YR,A,F,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Diabetes mellitus;Pregnancy;Treatment noncompliance,109841151,OT,,,109841151,1,201102,,,,109841151,1,Product used for unknown indication
10984145,109841451,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0146085,GILEAD,,64,YR,A,F,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Diabetes mellitus;Treatment noncompliance,109841451,OT,,,109841451,1,201309,,,,109841451,1,Product used for unknown indication
10984181,109841811,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145408,GILEAD,,60,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Cardiovascular disorder;Drug ineffective;Drug resistance;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Neoplasm malignant,109841811,OT,,,109841811,1,200711,,,,109841811,1,Product used for unknown indication
10984289,109842891,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0146133,GILEAD,,40,YR,A,F,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Treatment noncompliance,109842891,OT,,,,,,,,,109842891,1,Product used for unknown indication
10984349,109843491,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0146215,GILEAD,,22,YR,A,,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Drug resistance;Treatment noncompliance,109843491,OT,,,109843491,1,201502,,,,109843491,1,Product used for unknown indication
10984455,109844551,1,I,,20150325,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145955,GILEAD,,31,YR,A,M,Y,,,20150403,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes abnormal;Diabetes mellitus;Treatment noncompliance,109844551,OT,,,109844551,1,201308,,,,109844551,1,Product used for unknown indication
10991102,109911021,1,I,20150129,20150209,20150406,20150406,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-009061,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20150406,N,CN,KE,KE,EFAVIRENZ,Death;Muscular weakness;Tuberculosis,109911021,DE,,,109911021,1,20141001,,,,109911021,1,Antiretroviral therapy
10991801,109918012,2,F,20141030,20150412,20150406,20150420,EXP,,CN-GILEAD-2015-0146232,GILEAD,,64,YR,A,F,Y,64,KG,20150420,N,MD,CN,CN,EFAVIRENZ,Blood creatinine increased;Multi-organ failure;Oliguria,109918012,OT,,,109918012,1,20141030,20141111,,,109918012,1,Acquired immunodeficiency syndrome
10992538,109925381,1,I,,20150326,20150406,20150406,EXP,GB-MHRA-ADR 22914347,GB-GILEAD-2015-0145147,GILEAD,,60,YR,A,M,Y,,,20150406,N,CN,GB,GB,SUSTIVA,Hand fracture,109925381,OT,,,,,,,,,109925381,1,Product used for unknown indication
10993190,109931901,1,I,20141202,20150213,20150407,20150407,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-011026,BRISTOL MYERS SQUIBB,,62,YR,,F,Y,,,20150407,N,OT,UG,UG,EFAVIRENZ,Death;Lymph node tuberculosis;Sepsis,109931901,DE,,,109931901,1,20150107,20150112,,,109931901,1,Antiretroviral therapy
10998311,109983111,1,I,200905,20150323,20150406,20150406,EXP,,BR2015GSK043089,VIIV,,29,YR,,M,N,,,20150401,N,OT,BR,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Immune reconstitution inflammatory syndrome;Inflammation;Lymphadenopathy;Mucocutaneous leishmaniasis;Myiasis;Nasal obstruction;Skin necrosis;Skin ulcer;Swelling,109983111,OT,109983111,HP,109983111,1,200812,,,,109983111,1,HIV infection
11001425,110014251,1,I,,20150326,20150408,20150408,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-019877,BRISTOL MYERS SQUIBB,,62,YR,,M,Y,,,20150408,N,CN,GB,GB,SUSTIVA,Lower respiratory tract infection,110014251,OT,,,,,,,,,110014251,1,Product used for unknown indication
11002842,110028421,1,I,20150310,20150327,20150408,20150408,EXP,,BW-GILEAD-2015-0146397,GILEAD,,39,YR,A,M,Y,,,20150408,N,MD,BW,BW,EFAVIRENZ,VIIth nerve paralysis,110028421,HO,,,110028421,1,20091118,20150226,,,110028421,1,HIV infection
11003005,110030051,1,I,,20150326,20150408,20150408,EXP,,GB-MYLANLABS-2015M1011463,MYLAN,"FERNANDO I, SCOTT G. A CASE OF MULTICENTRIC CASTLEMAN^S DISEASE IN HIV INFECTION WITH THE RARE COMPLICATION OF ACQUIRED ANGIOEDEMA. INT-J-STD-AIDS 2014; 25(7):523-525.",,,,,Y,,,20150408,N,OT,GB,GB,EFAVIRENZ,Castleman's disease;Idiopathic angioedema;Immune reconstitution inflammatory syndrome,110030051,OT,,,,,,,,,110030051,1,Genital herpes
11003783,110037831,1,I,2008,20150326,20150409,20150409,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-022290,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20150409,N,OT,GB,GB,EFAVIRENZ,Angioedema;Castleman's disease;Immune reconstitution inflammatory syndrome,110037831,HO,,,110037831,1,200403,,,,110037831,1,HIV infection
11005139,110051392,2,F,,20150417,20150409,20150422,EXP,,JP-GLAXOSMITHKLINE-JP2015JPN045663,GLAXOSMITHKLINE,"WADA T, ET AL.. A CASE OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION PRESENTING WITH VARIOUS IMMUNE ABNORMALITIES. THE JOURNAL OF THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES. 2015;89:290",68,YR,,M,Y,,,20150422,N,MD,JP,JP,Efavirenz,Anaemia;Anti-GAD antibody positive;Antimitochondrial antibody positive;Antinuclear antibody positive;Autoantibody positive;Calculus urinary;Cutaneous lupus erythematosus;DNA antibody positive;Glycosylated haemoglobin increased;Hepatic function abnormal;Immunology test abnormal;Rash;Type 1 diabetes mellitus,110051392,OT,,,,,,,,,110051392,3,Acquired immunodeficiency syndrome
11005236,110052361,1,I,20140512,20150217,20150409,20150409,EXP,,SZ-GILEAD-2015-0141083,GILEAD,,0,YR,,M,Y,3.5,KG,20150409,N,MD,SZ,SZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foot deformity,110052361,CA,,,110052361,1,20140512,,,,110052361,1,HIV infection
11011237,110112373,3,F,,20150407,20150410,20150416,EXP,,CA-ABBVIE-15P-028-1372603-00,ABBVIE,,52,YR,,M,Y,,,20150416,N,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110112373,OT,,,,,,,,,110112373,1,HIV infection
11018783,110187832,2,F,,20150205,20150412,20150524,PER,,US-JNJFOC-20150208265,JANSSEN,"CASTILLO JJ, REAGAN J, SIKOV W, WINER E. BORTEZOMIB IN COMBINATION WITH INFUSION DOSE-ADJUSTED EPOCH FOR THE TREATMENT OF PLASMABLASTIC LYMPHOMA. BR J HAEMATOL 22-JAN-2015;13300.",40,YR,A,M,Y,,,20150524,N,MD,US,US,EFAVIRENZ,Herpes zoster;Off label use;Therapeutic response unexpected;Thrombocytopenia,110187832,OT,,,,,,,,,110187832,1,Plasmablastic lymphoma
11021180,110211801,1,I,,20150402,20150413,20150413,EXP,,BY-CIPLA LTD.-2015BY02778,CIPLA,"SVETLANA SETKINA, MARINA DOTSENKO, SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA, ELENA KOZOREZ, ALENA DODALEVA, NATALIA ROSSA. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF",,,,,Y,,,20150413,N,OT,BY,BY,Efavirenz,Hypoaesthesia oral,110211801,OT,,,,,,,,,110211801,1,HIV infection
11021435,110214351,1,I,20150202,20150403,20150413,20150413,EXP,,ES-GILEAD-2015-0147410,GILEAD,,39,YR,A,F,Y,61.5,KG,20150413,N,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ectopic pregnancy,110214351,OT,,,110214351,1,20100628,,,,110214351,1,HIV infection
11022075,110220752,2,F,201501,20150421,20150413,20150504,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-020219,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,68,KG,20150504,N,CN,US,UG,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Uterine haemorrhage,110220752,HO,,,110220752,1,20131021,20131002,,,110220752,1,HIV infection
11022204,110222042,2,F,20150218,20150428,20150413,20150501,EXP,ZA-ANRS-201500264,ZA-GILEAD-2015-0147988,GILEAD,,42,YR,A,M,Y,48.6,KG,20150501,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Hypokalaemia;Renal failure,110222042,OT,,,110222042,1,20130405,,,,110222042,1,HIV infection
11022257,110222571,1,I,,20150407,20150413,20150413,EXP,,CA-ABBVIE-15P-028-1373193-00,ABBVIE,,52,YR,,M,Y,,,20150413,N,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110222571,OT,,,,,,,,,110222571,1,Product used for unknown indication
11024072,110240721,1,I,,20150407,20150413,20150413,EXP,,CA-ABBVIE-15P-028-1372646-00,ABBVIE,,52,YR,,M,Y,,,20150413,N,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110240721,OT,,,,,,,,,110240721,1,HIV infection
11024230,110242302,2,F,,20150407,20150413,20150416,EXP,,CA-ABBVIE-15P-028-1372737-00,ABBVIE,,,,,M,Y,,,20150416,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110242302,OT,,,,,,,,,110242302,1,Product used for unknown indication
11024231,110242311,1,I,,20150407,20150413,20150413,EXP,,CA-ABBVIE-15P-028-1372683-00,ABBVIE,,54,YR,,M,Y,,,20150413,N,OT,CA,CA,SUSTIVA,Depression;Drug interaction,110242311,OT,,,,,,,,,110242311,1,Product used for unknown indication
11024240,110242401,1,I,,20150407,20150414,20150414,EXP,,CA-ABBVIE-15P-028-1373252-00,ABBVIE,,,,,M,Y,,,20150413,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110242401,OT,,,,,,,,,110242401,1,Product used for unknown indication
11024241,110242411,1,I,,20150407,20150414,20150414,EXP,,CA-ABBVIE-15P-028-1373536-00,ABBVIE,,,,,M,Y,,,20150413,N,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110242411,OT,,,,,,,,,110242411,1,Product used for unknown indication
11024262,110242621,1,I,20150312,20150407,20150414,20150414,EXP,,IN-AUROBINDO-AUR-APL-2015-03094,AUROBINDO,,22,YR,,F,Y,,,20150413,N,MD,IN,IN,EFAVIRENZ TABLETS 600 MG,Rash maculo-papular,110242621,OT,,,110242621,1,20150305,20150312,,,110242621,1,HIV infection
11024290,110242901,1,I,,20150402,20150414,20150414,EXP,,BY-CIPLA LTD.-2015BY02779,CIPLA,"SVETLANA SETKINA, MARINA DOTSENKO, SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA, ELENA KOZOREZ, ALENA DODALEVA, NATALIA ROSSA. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF. 2015",,,,,Y,,,20150414,N,OT,BY,BY,Efavirenz,Loss of consciousness,110242901,OT,,,,,,,,,110242901,1,HIV infection
11024291,110242911,1,I,,20150402,20150414,20150414,EXP,,BY-CIPLA LTD.-2015BY02805,CIPLA,"SVETLANA SETKINA,  MARINA DOTSENKO,  SVIATLANA BONDAR, IRYNA CHARNYSH, ALLA KUCHKO, ALENA KAZNACHEEVA ET AL.. SAFETY AND EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN TREATMENT-NA??VE HIV PATIENTS: PRELIMINARY FINDINGS OF A COHORT EVENT MONITORING STUDY IN BELARUS. DRUG SAF. 2015;1 TO 8",,,,,Y,,,20150414,N,OT,BY,BY,Efavirenz,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome,110242911,OT,,,,,,,,,110242911,1,HIV test positive
11024851,110248512,2,F,,20150417,20150410,20150424,EXP,,JP2015JPN045663,VIIV,,68,YR,,M,N,,,20150421,N,MD,JP,,EFAVIRENZ (EFAVIRENZ),Anaemia;Anti-GAD antibody positive;Antimitochondrial antibody positive;Antinuclear antibody positive;Autoantibody positive;Calculus urinary;Cutaneous lupus erythematosus;DNA antibody positive;Glycosylated haemoglobin increased;Hepatic function abnormal;Immunology test abnormal;Rash;Type 1 diabetes mellitus,110248512,OT,110248512,FGN,,,,,,,110248512,2,Acquired immunodeficiency syndrome
11026977,110269772,2,F,,20121211,20150414,20150525,PER,,US-JNJFOC-20121211125,JANSSEN,"SEVINSKY H, ELEY T, PERSSON A, GARNER D, YONES C, NETTLES R, ET AL. THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND NORGESTIMATE IN HEALTHY HIV-NEGATIVE WOMEN. ANTIVIRAL THERAPY 2011;16:149-156.",,,,F,Y,,,20150525,N,OT,US,US,EFAVIRENZ,Drug interaction;Headache;Metrorrhagia,,,,,,,,,,,110269772,1,Contraception
11026981,110269812,2,F,,20140909,20150414,20150525,PER,,US-JNJFOC-20121211123,JANSSEN,"SEVINSKY H, ELEY T, PERSSON A, GARNER D, YONES C, NETTLES R, ET AL. THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND NORGESTIMATE IN HEALTHY HIV-NEGATIVE WOMEN. ANTIVIRAL THERAPY 2011;16:149-156.",,,,F,Y,,,20150525,N,OT,US,US,EFAVIRENZ,Headache,,,,,,,,,,,110269812,1,Contraception
11031902,110319022,2,F,20140814,20150422,20150415,20150428,EXP,,UG-GLAXOSMITHKLINE-UG2015GSK050860,GLAXOSMITHKLINE,,48,YR,,M,Y,,,20150428,N,MD,UG,UG,EFAVIRENZ,Anaemia,110319022,DE,,,110319022,1,20140527,20140821,,,110319022,1,HIV infection
11038596,110385961,1,I,,20150410,20150416,20150416,EXP,,US-BMSGILMSD-2015-0148761,GILEAD,,,,,M,Y,,,20150416,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Hip fracture,110385961,OT,,,,,,,,,110385961,1,HIV infection
11038763,110387631,1,I,,20150325,20150416,20150416,EXP,,US-BMSGILMSD-2015-0146158,GILEAD,,43,YR,A,,Y,,,20150416,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant;Treatment noncompliance,110387631,OT,,,110387631,1,201404,,,,110387631,1,Product used for unknown indication
11040640,110406401,1,I,,20150325,20150416,20150416,EXP,,US-BMSGILMSD-2015-0146162,GILEAD,,50,YR,A,F,Y,,,20150416,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Hypertension,110406401,OT,,,110406401,1,201410,,,,110406401,1,Product used for unknown indication
11042847,110428472,2,F,200408,20150424,20150417,20150504,EXP,,GB-AUROBINDO-AUR-APL-2015-03298,AUROBINDO,"FERNANDO I, ET AL.. EFAVIRENZ/LAMIVUDINE/TENOFOVIR: MULTICENTRIC CASTLEMAN^S DISEASE AND ACQUIRED ANGIOEDEMA IN THE CONTEXT OF IRIS: CASE REPORT. REACTIONS WEEKLY. 2015;1546:101",37,YR,,F,Y,,,20150504,N,OT,GB,GB,Efavirenz,Anaemia;Angioedema;CD4 lymphocytes increased;Castleman's disease;Condition aggravated;Haemoglobin decreased;Haemolysis;Peripheral swelling;Pruritus;Swelling face;Viral load decreased,110428472,HO,,,110428472,1,2004,,,,110428472,1,Genital herpes
11043901,110439011,1,I,,20150406,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02905,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN:A REVIEW OF ITS USE IN HIV-1 INFECTION. DRUGS. 2015;75:503-514,,,,,Y,,,20150417,N,OT,NZ,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Pneumonia,110439011,DE,,,,,,,,,110439011,1,HIV infection
11043906,110439061,1,I,,20150406,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02899,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN: A REVIEW OF ITS USE IN HIV-1 INFECTION.. DRUGS. DRUG;75:503-514,,,,,Y,,,20150417,N,OT,NZ,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Renal failure;Sepsis,110439061,DE,,,,,,,,,110439061,1,HIV infection
11044115,110441151,1,I,,20150331,20150415,20150415,EXP,,FK201501717,FRESENIUS KABI,,44,YR,,M,N,,,20150409,N,,US,,EFAVIRENZ,Drug interaction;Febrile neutropenia;Neuropathy peripheral,110441151,OT,110441151,HP,,,,,,,110441151,1,HIV infection
11045212,110452121,1,I,,20150406,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02915,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN: A REVIEW OF ITS USE IN HIV-1 INFECTION.. DRUGS. DRUG;75:503-514,,,,,Y,,,20150418,N,,COUNTRY NOT SPECIFIED,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Cerebrovascular accident,110452121,OT,,,,,,,,,110452121,1,HIV infection
11048605,110486051,1,I,,20150407,20150420,20150420,EXP,,CM-GLAXOSMITHKLINE-CM2015GSK046410,GLAXOSMITHKLINE,"WANDA F, ET AL.. CLINICAL FEATURES AND MANAGEMENT OF A SEVERE PARADOXICAL REACTION ASSOCIATED WITH COMBINED TREATMENT OF BURULI ULCER AND HIV CO-INFECTION.. BMC INFECTIOUS DISEASES. 2014;14",30,YR,,M,Y,,,20150420,N,OT,CM,CM,Efavirenz,Hypersensitivity;Inflammation;Necrosis;Oedema;Paradoxical drug reaction;Pruritus generalised;Pyrexia;Rash pustular;Skin lesion;Ulcer,110486051,OT,,,110486051,1,20130109,20130303,,,110486051,1,Mycobacterium ulcerans infection
11048742,110487421,1,I,,20150407,20150420,20150420,EXP,,IN-CIPLA LTD.-2015IN02964,CIPLA,"PAL.A, SARKAR.S, SAHA.D, GUHA.S, SAHA.B, CHAKRAVARTY.R, CHAKRABARTI.S. HIGH INCIDENCE OF LAMIVUDINE-RESISTANCE ASSOCIATED VACCINE-ESCAPE HBV MUTANT AMONG HIV-COINFECTED PATIENTS ON PROLONGED ANTIRETROVIRAL ACTIVITY. ISSN. 2015;1359-6535:1-20",,,,,Y,,,20150420,N,OT,IN,IN,NEVIRAPINE/EFAVIRENZ,Death,110487421,DE,,,,,,,,,110487421,1,HIV infection
11048771,110487711,1,I,,20150407,20150420,20150420,EXP,,IN-CIPLA LTD.-2015IN02963,CIPLA,"PAL.A, SARKAR.S, SAHA.D, GUHA.S, SAHA.B, CHAKRAVARTY.R, CHAKRABARTI.S. HIGH INCIDENCE OF LAMIVUDINE-RESISTANCE ASSOCIATED VACCINE-ESCAPE HBV MUTANT AMONG HIV-COINFECTED PATIENTS ON PROLONGED ANTIRETROVIRAL ACTIVITY. ISSN. 2015;1359-6535",,,,,Y,,,20150420,N,OT,IN,IN,NEVIRAPINE/EFAVIRENZ,Fibrosis,110487711,OT,,,,,,,,,110487711,1,HIV infection
11050632,110506322,2,F,20140814,20150422,20150417,20150430,EXP,,UG2015GSK050860,VIIV,,48,YR,,M,N,,,20150427,N,MD,UG,,EFAVIRENZ (EFAVIRENZ),Anaemia;Dehydration;Pallor,110506322,DE,110506322,HP,110506322,1,20140527,20140821,,,110506322,1,HIV infection
11054474,110544741,1,I,,20150413,20150422,20150422,EXP,,CH-CIPLA LTD.-2015CH03145,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1 TO 20",,,,,Y,,,20150422,N,OT,CH,CH,Efavirenz,Hepatic steatosis;Hepatitis C,110544741,DE,,,,,,,,,110544741,1,HIV test positive
11054476,110544761,1,I,,20150413,20150422,20150422,EXP,,CH-CIPLA LTD.-2015CH03136,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1 TO 20",,,,,Y,,,20150422,N,OT,CH,CH,Efavirenz,Sepsis,110544761,DE,,,,,,,,,110544761,1,HIV test positive
11054477,110544771,1,I,,20150413,20150422,20150422,EXP,,CH-CIPLA LTD.-2015CH03142,CIPLA,"NATHAN FORD, ZARA SHUBBER, ANTON POZNIAK, MARCO VITORIA, MEG DOHERTY, CATHERINE KIRBY, ALEXANDRA CALMY. COMPARATIVE SAFETY AND NEUROPSYCHIATRIC ADVERSE EVENTS ASSOCIATED WITH EFAVIRENZ USE IN FIRST-LINE ANTIRETROVIRAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1 TO 20",,,,,Y,,,20150422,N,OT,CH,CH,Efavirenz,Lactic acidosis,110544771,DE,,,,,,,,,110544771,1,HIV test positive
11055572,110555721,1,I,20150112,20150319,20150422,20150422,EXP,,US-009507513-1503GBR013971,MERCK,,12,YR,,M,Y,,,20150422,N,CN,US,KE,EFAVIRENZ,Gastroenteritis,110555721,HO,,,,,,,,,110555721,1,HIV infection
11055951,110559513,3,F,20150323,20150608,20150422,20150616,EXP,,ZA-GILEAD-2015-0149662,GILEAD,,32,YR,A,F,Y,83.8,KG,20150616,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Xanthoma,110559513,OT,,,110559513,1,20140407,20150302,,,110559513,1,HIV infection
11058479,110584791,1,I,,20150407,20150421,20150421,EXP,,CM2015GSK046410,VIIV,,30,YR,,M,N,,,20150420,N,OT,CM,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Hypersensitivity;Oedema peripheral;Paradoxical drug reaction;Pruritus generalised;Pyrexia;Rash pustular;Skin graft;Skin lesion;Soft tissue inflammation;Ulcer;Wound necrosis,110584791,RI,110584791,FGN,110584791,1,20130109,20130303,,,110584791,1,Mycobacterium ulcerans infection
11069342,110693421,1,I,20141216,20150421,20150427,20150427,EXP,,US-GILEAD-2015-0149983,GILEAD,,50,YR,A,M,Y,72.5,KG,20150427,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Schizoaffective disorder,110693421,HO,,,110693421,1,20100511,201411,,,110693421,1,HIV infection
11069569,110695691,1,I,20140816,20150420,20150427,20150427,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK055115,GLAXOSMITHKLINE,,60,YR,,M,Y,,,20150427,N,MD,CN,CN,EFAVIRENZ,Hypersensitivity,110695691,OT,,,110695691,1,20140812,20140826,,,110695691,1,HIV infection
11070860,110708601,1,I,20150407,20150415,20150428,20150428,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-025652,BRISTOL MYERS SQUIBB,,54,YR,,F,Y,,,20150428,N,CN,TW,TW,EFAVIRENZ,Abdominal pain;Pyrexia,110708601,HO,,,110708601,1,20141108,,,,110708601,1,HIV infection
11071414,110714141,1,I,,20150421,20150428,20150428,EXP,,GB-CIPLA LTD.-2015GB03323,CIPLA,"PINOGES.L, SCHRAMM.B, POULET.E, BALKAN.S, SZUMILIN.E, FERREYRA.C, PUJADES-RODRIGUEZ.M,. RISK FACTORS AND MORTALITY ASSOCIATED WITH RESISTANCE TO FIRST-LINE ANTIRETROVIRAL THERAPY: MULTICENTRIC CROSS-SECTIONAL AND LONGITUDINAL ANALYSES. J ACQUIR IMMUNE DEFIC SYNDR. 2015;68:1-9",,,,,Y,,,20150428,N,OT,GB,GB,Efavirenz,Death;Drug resistance;Treatment noncompliance,110714141,DE,,,,,,,,,,,
11071415,110714151,1,I,,20150421,20150428,20150428,EXP,,GB-CIPLA LTD.-2015UA03341,CIPLA,"PINOGES.L, SCHRAMM.B, POULET.E, BALKAN.S, SZUMILIN.E, FERREYRA.C, PUJADES-RODRIGUEZ.M.. RISK FACTORS AND MORTALITY ASSOCIATED WITH RESISTANCE TO FIRST-LINE ANTIRETROVIRAL THERAPY: MULTICENTRIC CROSS-SECTIONAL AND LONGITUDINAL ANALYSES. J ACQUIR IMMUNE DEFIC SYNDR. 2015;68:1-9",,,,,Y,,,20150428,N,OT,GB,GB,Efavirenz,Death;Virologic failure,110714151,OT,,,,,,,,,,,
11072338,110723381,1,I,20150412,20150422,20150428,20150428,EXP,,MW-009507513-1504MWI021776,MERCK,,39,YR,,F,Y,,,20150428,N,CN,MW,MW,EFAVIRENZ,Lower respiratory tract infection,110723381,HO,,,110723381,1,20150324,,,,110723381,1,Antiretroviral therapy
11072967,110729671,1,I,,20150423,20150428,20150428,EXP,,US-BMSGILMSD-2015-0150542,GILEAD,,50,YR,A,M,Y,,,20150428,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ear deformity acquired;Hypersensitivity;Injury,110729671,HO,,,,,,,,,110729671,1,HIV infection
11073050,110730501,1,I,,20150420,20150428,20150428,EXP,,UG-GLAXOSMITHKLINE-UG2015GSK057314,GLAXOSMITHKLINE,"MUSUBIRE AK, MEYA DB, LUKANDE R, KAMBUGU A, BOHJANEN PR, BOULWARE DR. GASTROINTESTINALCRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MEDICAL MYCOLOGY CASE REPORTS. 2015;8:40-43",37,YR,,M,Y,,,20150428,N,OT,UG,UG,Efavirenz,Abdominal pain;Abdominal tenderness;Cough;Cryptococcosis;Immune reconstitution inflammatory syndrome;Pyrexia;Tachypnoea;Vomiting,110730501,OT,,,110730501,1,20090611,,,,110730501,1,HIV infection
11073417,110734171,1,I,,20150224,20150428,20150428,EXP,,US-BMSGILMSD-2015-0139742,GILEAD,,,,,F,Y,,,20150428,N,PH,US,US,SUSTIVA,Surgery,110734171,HO,,,,,,,,,110734171,1,Product used for unknown indication
11074210,110742101,1,I,20150415,,20150428,20150428,DIR,,,,,34,YR,,M,N,73.9,KG,20150427,N,OT,US,,SUSTIVA,Chest discomfort;Chest pain;Infusion related reaction,,,110742101,HP,,,,,,,110742101,1,Anaemia
11074857,110748571,1,I,,20150421,20150429,20150429,EXP,,GB-CIPLA LTD.-2015GB03346,CIPLA,"LORETXU PINOGES, BIRGIT SCHRAMM, ELISABETH POULET, SUNA BALKAN, ELISABETH SZUMILIN, CECILIA FERREYRA, MAR PUJADES-RODR?GUEZ. RISK FACTORS AND MORTALITY ASSOCIATED WITH RESISTANCE TO FIRST-LINE ANTIRETROVIRAL THERAPY: MULTICENTRIC CROSS-SECTIONAL AND LONGITUDINAL ANALYSES. J ACQUIR IMMUNE DEFIC SYNDR. 2015;68:527-535",,,,,Y,,,20150429,N,OT,GB,GB,Efavirenz,Death;Drug resistance,110748571,OT,,,,,,,,,,,
11075781,110757811,1,I,,20150421,20150429,20150429,EXP,,PR-CIPLA LTD.-2015PR03348,CIPLA,"RODRIGUEZ-TORRES M, GAGGAR A, SHEN G, KIRBY B, SVAROVSKAIA E, BRAINARD D, SYMONDS WT, MCHUTCHISON JG, GONZALEZ M, RODRIGUEZ-ORENGO J. SOFOSBUVIR FOR CHRONIC HEPATITIS C VIRUS INFECTION GENOTYPE 1-4 IN PATIENTS COINFECTED WITH HIV. J ACQUIR IMMUNE DEFIC SYNDR. 2015;68:543-549",,,,,Y,,,20150429,N,OT,PR,PR,Tenofovir/Emtricitabine/Efavirenz,Treatment failure,110757811,OT,,,,,,,,,110757811,1,Chronic hepatitis C
11075935,110759351,1,I,20140926,20150420,20150429,20150429,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK054512,GLAXOSMITHKLINE,,36,YR,,F,Y,,,20150429,N,MD,CN,CN,Efavirenz,Dermatitis allergic,110759351,HO,,,110759351,1,20140905,20140928,,,110759351,1,Acquired immunodeficiency syndrome
11075940,110759401,1,I,20140221,20150420,20150429,20150429,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK054510,GLAXOSMITHKLINE,,61,YR,,M,Y,,,20150429,N,MD,CN,CN,Efavirenz,Anaemia;Hepatocellular injury;Off label use,110759401,OT,,,110759401,1,20140221,20140829,,,110759401,1,Acquired immunodeficiency syndrome
11076644,110766441,1,I,20130917,20131001,20150429,20150429,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19681527,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20150429,N,CN,US,UG,EFAVIRENZ,Bronchopneumonia;Cryptosporidiosis infection;Death,110766441,LT,,,110766441,1,20130902,20130904,,,110766441,1,HIV infection
11078602,110786021,1,I,2007,20150420,20150428,20150428,EXP,,RU2015GSK055184,VIIV,,28,YR,,F,N,,,20150426,N,CN,RU,,STOCRIN (EFAVIRENZ),Abdominal pain;Abortion induced;Alopecia;Burning sensation;Dermatitis allergic;Dry skin;Haemoglobin decreased;Hair colour changes;Lymphadenopathy;Maternal exposure during pregnancy;Nasal congestion;Nightmare;Pancreatic disorder;Pruritus;Rash erythematous;Tuberculosis,110786021,OT,110786021,CSM,110786021,1,2007,2007,,,110786021,1,Prophylaxis
11078607,110786071,1,I,20140816,20150420,20150428,20150428,EXP,,CN2015GSK055115,VIIV,,60,YR,,M,N,,,20150426,N,MD,CN,,EFAVIRENZ,Hypersensitivity,110786071,OT,110786071,HP,110786071,1,20140812,20140826,,,110786071,1,HIV infection
11078846,110788461,1,I,20060101,,20150429,20150429,DIR,,,,,41,YR,,F,N,,,20150427,N,,COUNTRY NOT SPECIFIED,,SUSTIVA,Blood cholesterol increased,,,,,110788461,1,20060101,,,,,,
11078929,110789292,2,F,20150412,20150511,20150430,20150514,EXP,,MW-GILEAD-2015-0150435,GILEAD,,39,YR,A,F,Y,,,20150514,N,MD,MW,MW,EFAVIRENZ,Lower respiratory tract infection,110789292,OT,,,110789292,1,20150324,,,,110789292,1,HIV infection
11079990,110799903,3,F,20150407,20150518,20150430,20150601,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-026377,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,61,KG,20150601,N,CN,MW,MW,EFAVIRENZ,Neutropenia,110799903,LT,,,110799903,1,20140502,20150122,,,110799903,1,HIV infection
11082112,110821121,1,I,,20150421,20150501,20150501,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK058611,GLAXOSMITHKLINE,"GKENTZI D, TEBRUEGGE M, TUDOR-WILLIAMS G, WALTERS S, LYALL H, SHARLAND M ET AL. INCIDENCE, SPECTRUM AND OUTCOME OF IMMUNE RECONSTITUTION SYNDROME IN HIV-INFECTED CHILDREN AFTER INITIATION OF ANTIRETROVIRAL THERAPY. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2014;33:9",8,YR,,F,Y,,,20150501,N,MD,GB,GB,Efavirenz,Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Mechanical ventilation;Mycobacterium avium complex infection;Respiratory disorder;Tuberculosis,110821121,DE,,,,,,,,,110821121,1,HIV infection
11082121,110821211,1,I,,20150421,20150501,20150501,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK059254,GLAXOSMITHKLINE,"GKENTZI D, TEBRUEGGE M, TUDOR-WILLIAMS G, WALTERS S, LYALL H, SHARLAND M ET AL. INCIDENCE, SPECTRUM AND OUTCOME OF IMMUNE RECONSTITUTION SYNDROME IN HIV-INFECTED CHILDREN AFTER INITIATION OF ANTIRETROVIRAL THERAPY. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2014;33:9",14,YR,,M,Y,,,20150501,N,MD,GB,GB,Efavirenz,Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Granuloma;Hepatomegaly;Immune reconstitution inflammatory syndrome;Lung infiltration;Mycobacterium avium complex infection;Pleural effusion;Pyrexia;Respiratory disorder,110821211,DE,,,,,,,,,110821211,1,HIV infection
11087763,110877631,1,I,,20150424,20150430,20150430,EXP,,UG2015GSK057314,VIIV,,37,YR,,M,N,,,20150428,N,OT,UG,,EFAVIRENZ,Abdominal pain;Abdominal tenderness;Adhesion;Appendix disorder;Cough;Cryptococcosis;Immune reconstitution inflammatory syndrome;Intestinal perforation;Lymphadenopathy;Mass;Peritonitis;Pneumoperitoneum;Pyrexia;Tachypnoea;Vomiting,110877631,OT,110877631,LIT,110877631,1,20090611,,,,110877631,1,HIV infection
11088152,110881521,1,I,20140926,20150420,20150430,20150430,EXP,,CN2015GSK054512,VIIV,,36,YR,,F,N,,,20150429,N,MD,CN,,EFAVIRENZ,Dermatitis allergic,110881521,HO,110881521,FGN,110881521,1,20140905,20140928,,,110881521,1,Acquired immunodeficiency syndrome
11088175,110881751,1,I,20140221,20150420,20150430,20150430,EXP,,CN2015GSK054510,VIIV,,61,YR,,M,N,,,20150429,N,MD,CN,,EFAVIRENZ (EFAVIRENZ) TABLET,Anaemia;Drug-induced liver injury;Hepatocellular injury;Off label use,110881751,HO,110881751,HP,110881751,1,20140221,20140829,,,110881751,1,Acquired immunodeficiency syndrome
11091473,110914731,1,I,2014,20150430,20150505,20150505,EXP,,US-BMSGILMSD-2015-0151744,GILEAD,,,,,F,Y,,,20150505,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,110914731,HO,,,,,,,,,110914731,1,HIV infection
11092149,110921491,1,I,201502,20150422,20150505,20150505,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-027008,BRISTOL MYERS SQUIBB,,61,YR,,F,Y,,,20150505,N,CN,FR,FR,SUSTIVA,Nephropathy,110921491,OT,,,110921491,1,20040614,20150224,,,110921491,1,HIV infection
11092387,110923871,1,I,,20150421,20150504,20150504,EXP,,GB2015GSK058611,VIIV,,8,YR,,F,N,,,20150501,N,MD,GB,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,General physical health deterioration;Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Multi-organ failure;Mycobacterium avium complex infection;Respiratory disorder;Tuberculosis,110923871,OT,110923871,LIT,,,,,,,110923871,1,HIV infection
11092389,110923891,1,I,,20150421,20150504,20150504,EXP,,GB2015GSK059254,VIIV,,14,YR,,M,N,,,20150501,N,,GB,,EFAVIRENZ (EFAVIRENZ),Abdominal lymphadenopathy;Abdominal pain;Diarrhoea;Granuloma;Hepatomegaly;Immune reconstitution inflammatory syndrome;Lung infiltration;Mycobacterium avium complex infection;Pleural effusion;Pyrexia;Respiratory disorder,110923891,DE,110923891,HP,,,,,,,110923891,1,HIV infection
11092579,110925791,1,I,2009,20150420,20150504,20150504,EXP,,RU2015GSK054554,VIIV,,,,,F,N,,,20150430,N,CN,RU,,STOCRIN (EFAVIRENZ),Abnormal dreams;Caesarean section;Diarrhoea;Dizziness;Exposure during pregnancy;Haemoglobin decreased;Hepatic cirrhosis;Insomnia;Jaundice;Lipodystrophy acquired;Memory impairment;Nausea;Platelet count decreased;Pregnancy;Premature delivery;Toxic skin eruption;Viral load increased,110925791,HO,110925791,CSM,110925791,1,2009,20150405,,,110925791,1,HIV infection
11092598,110925981,1,I,,20150430,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03502,CIPLA,,,,,,Y,,,20150506,N,OT,UG,UG,Efavirenz,Abnormal behaviour;Aggression;Insomnia;Psychomotor hyperactivity,110925981,OT,,,,,,,,,110925981,1,HIV infection
11092643,110926431,1,I,,20150430,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03473,CIPLA,,,,,,Y,,,20150506,N,OT,UG,UG,Efavirenz,Dyskinesia;Gynaecomastia,110926431,OT,,,,,,,,,,,
11092667,110926671,1,I,,20150430,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03475,CIPLA,,,,,,Y,,,20150506,N,OT,UG,UG,Efavirenz,Affective disorder;Insomnia,110926671,OT,,,,,,,,,,,
11092692,110926921,1,I,,20150430,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03477,CIPLA,,,,,,Y,,,20150506,N,OT,UG,UG,Efavirenz,Adverse drug reaction,110926921,OT,,,,,,,,,,,
11092775,110927751,1,I,,20150430,20150506,20150506,EXP,,UG-CIPLA LTD.-2015UG03469,CIPLA,,,,,,Y,,,20150506,N,OT,UG,UG,Efavirenz,Mental disorder,110927751,OT,,,,,,,,,,,
11092896,110928961,1,I,2002,20150422,20150504,20150504,EXP,,US2015055006,VIIV,,,,,M,N,,,20150429,N,CN,US,,SUSTIVA,Bedridden;Depression;Facial wasting;Fat redistribution;Fatigue;Suicide attempt,110928961,OT,110928961,CSM,110928961,1,2001,201409,,,110928961,1,HIV infection
11094172,110941722,2,F,20150416,20150514,20150506,20150520,EXP,,CO-GLAXOSMITHKLINE-CO2015GSK060517,GLAXOSMITHKLINE,,20,YR,,M,Y,179,KG,20150520,N,PH,CO,CO,EFAVIRENZ;Efavirenz,Drug hypersensitivity,110941722,LT,,,110941722,1,20150410,20150420,,,110941722,1,HIV infection
11094993,110949932,2,F,,20150514,20150506,20150521,EXP,,US-JAZZ-2015-US-006432,JAZZ,,,,,M,Y,,,20150521,N,MD,US,US,SUSTIVA,Drug hypersensitivity;Malabsorption;Multiple sclerosis;Psoriasis;Wrong technique in drug usage process,110949932,OT,,,110949932,1,201411,,,,110949932,1,Cataplexy
11100657,111006572,2,F,2015,20150521,20150508,20150528,EXP,,CA-ABBVIE-15P-028-1386416-00,ABBVIE,,,,,M,Y,72,KG,20150528,N,MD,COUNTRY NOT SPECIFIED,CA,TEVA EFAVIRENZ,Decreased appetite;Depression;Impaired work ability;Weight decreased,111006572,DS,,,111006572,1,20010712,,,,111006572,1,Antiretroviral therapy
11101158,111011582,2,F,201209,20150512,20150508,20150513,EXP,,US-BMSGILMSD-2015-0152313,GILEAD,,62,YR,A,M,Y,78.46,KG,20150513,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,111011582,OT,,,,,,,,,111011582,1,HIV infection
11101417,111014171,1,I,,20150430,20150508,20150508,EXP,,US-BMSGILMSD-2015-0151695,GILEAD,,,,,M,Y,,,20150508,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,111014171,OT,,,,,,,,,111014171,1,HIV infection
11103782,111037823,3,F,20150429,20150522,20150511,20150528,EXP,,BR-GILEAD-2015-0152280,GILEAD,,39,YR,A,M,Y,,,20150528,N,OT,BR,BR,EFAVIRENZ,Kaposi's sarcoma,111037823,OT,,,111037823,1,20150123,20150501,,,111037823,1,HIV infection
11104015,111040151,1,I,,20150507,20150511,20150511,EXP,,MW-GLAXOSMITHKLINE-MW2015GSK062927,GLAXOSMITHKLINE,"KUDZALA A, ET AL. CASE REPORT: A MAN ON ANTIRETROVIRAL THERAPY WITH PAINFUL THIGHS. MALAWI MEDICAL JOURNAL. 2013;25;1:24-25",54,YR,,M,Y,,,20150511,N,OT,MW,MW,Efavirenz,Arthropathy;Bone fragmentation;Hypersensitivity;Hypoaesthesia;Neuropathy peripheral;Osteoarthritis;Osteonecrosis;Osteosclerosis;Pain in extremity;Rash,111040151,OT,,,,,,,,,111040151,1,HIV infection
11104430,111044301,1,I,20140926,20150420,20150511,20150511,EXP,,CN-GLAXOSMITHKLINE-CN2015059462,GLAXOSMITHKLINE,,36,YR,,F,Y,38,KG,20150511,N,OT,CN,CN,Efavirenz,Dermatitis allergic,111044301,HO,,,111044301,1,20140905,20140928,,,111044301,1,Acquired immunodeficiency syndrome
11104431,111044311,1,I,20140728,20150420,20150511,20150511,EXP,,CN-GLAXOSMITHKLINE-CN2015059407,GLAXOSMITHKLINE,,61,YR,,M,Y,,,20150511,N,OT,CN,CN,Efavirenz,Hepatocellular injury,111044311,HO,,,111044311,1,20140508,20140829,,,111044311,1,Acquired immunodeficiency syndrome
11106687,111066871,1,I,,20150427,20150508,20150508,EXP,,FR2015GSK061402,VIIV,,23,YR,,M,N,,,20150507,N,MD,FR,,EFAVIRENZ (EFAVIRENZ),Drug dose omission;Immunodeficiency;Multiple-drug resistance;Nephropathy toxic;No therapeutic response;Pneumonia;Pyrexia,111066871,HO,111066871,HP,,,,,,,111066871,1,HIV infection
11106891,111068911,1,I,20140728,20150420,20150508,20150508,EXP,,CN2015059407,VIIV,,61,YR,,M,N,,,20150507,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Alanine aminotransferase increased;Aspartate aminotransferase increased;Bilirubin conjugated increased;Blood albumin decreased;Blood bilirubin increased;Blood bilirubin unconjugated increased;Drug-induced liver injury;Hepatocellular injury,111068911,OT,111068911,HP,111068911,1,20140508,20140829,,,111068911,1,Acquired immunodeficiency syndrome
11106918,111069181,1,I,201503,20150420,20150508,20150508,EXP,,RU2015GSK054546,VIIV,,,,,M,N,,,20150507,N,CN,RU,,"STOCRIN (EFAVIRENZ, EFAVIRENZ)",Dizziness;Feeling drunk;Mental retardation;Nausea;Vomiting,111069181,OT,111069181,FGN,111069181,1,20150326,,,,111069181,1,HIV infection
11106927,111069272,2,F,20150416,20150514,20150508,20150522,EXP,,CO2015GSK060517,VIIV,,20,YR,,M,N,179.0,KG,20150519,N,PH,CO,,EFAVIRENZ (EFAVIRENZ),Drug hypersensitivity,111069272,LT,111069272,HP,111069272,1,20150410,20150420,,,111069272,1,HIV infection
11107072,111070721,1,I,,20150508,20150512,20150512,EXP,,US-BMSGILMSD-2015-0152926,GILEAD,,45,YR,A,M,Y,,,20150512,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tuberculosis,111070721,LT,,,,,,,,,111070721,1,HIV infection
11110526,111105262,2,F,,20150511,20150513,20150518,EXP,,US-CIPLA LTD.-2015JP03695,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC.. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015;10 (5):1 TO 23",,,,,Y,,,20150518,N,OT,PL,US,Efavirenz,Lymphoma,111105262,DE,,,,,,,,,111105262,1,HIV infection
11111379,111113791,1,I,20150428,20150504,20150513,20150513,EXP,,UG-GILEAD-2015-0152101,GILEAD,,58,YR,A,M,Y,77,KG,20150513,N,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drowning,111113791,OT,,,111113791,1,20141208,20150427,,,111113791,1,HIV infection
11111546,111115461,1,I,,20150507,20150514,20150514,EXP,,FR-CIPLA LTD.-2015FR03693,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 10",,,,,Y,,,20150514,N,,COUNTRY NOT SPECIFIED,FR,Efavirenz,Death,111115461,DE,,,,,,,,,111115461,1,HIV infection
11111547,111115471,1,I,,20150507,20150514,20150514,EXP,,ES-CIPLA LTD.-2015JP03699,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL- NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE. 2015",,,,,Y,,,20150514,N,OT,PL,ES,Efavirenz,Adverse event,111115471,OT,,,,,,,,,111115471,1,HIV infection
11113155,111131551,1,I,20140816,20150420,20150512,20150512,EXP,,CN2015059410,VIIV,,60,YR,,M,N,,,20150508,N,OT,CN,,STOCRIN (EFAVIRENZ),Drug eruption;Hypersensitivity,111131551,OT,111131551,FGN,111131551,1,20140812,20140826,,,111131551,1,HIV infection
11113185,111131851,1,I,20140926,20150420,20150512,20150512,EXP,,CN2015059462,VIIV,,36,YR,,F,N,38.0,KG,20150508,N,OT,CN,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Dermatitis allergic,111131851,HO,111131851,HP,111131851,1,20140905,20140928,,,111131851,1,Acquired immunodeficiency syndrome
11113913,111139132,2,F,20150407,20150521,20150514,20150527,EXP,,MW-ABBVIE-15P-100-1388265-00,ABBVIE,,33,YR,,M,Y,61,KG,20150527,N,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Neutropenia,111139132,OT,,,111139132,1,20150122,20150121,,,111139132,1,HIV infection
11114137,111141373,3,F,20150212,20150528,20150514,20150603,EXP,,KE-GILEAD-2015-0152379,GILEAD,,46,YR,A,F,Y,35.7,KG,20150603,N,MD,KE,KE,EFAVIRENZ,Acute kidney injury;Cachexia;Drug-induced liver injury;Hepatitis B;Pulmonary tuberculosis,111141373,HO,,,111141373,1,20150121,20150415,,,111141373,1,HIV infection
11114820,111148201,1,I,,20150430,20150515,20150515,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-029333,BRISTOL MYERS SQUIBB,,,,,,Y,,,20150515,N,OT,US,US,EFAVIRENZ,Drug interaction;Medication error,,,,,,,,,,,111148201,1,Antiretroviral therapy
11115056,111150561,1,I,,20150505,20150515,20150515,EXP,,US-JNJFOC-20150503163,JANSSEN,,53,YR,A,F,Y,,,20150515,N,OT,US,US,EFAVIRENZ,Drug ineffective;Multiple-drug resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,111150561,OT,,,111150561,3,20131028,20140410,,,111150561,1,HIV infection
11115120,111151201,1,I,,20150511,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03777,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515,N,OT,PL,ES,Efavirenz,Progressive multifocal leukoencephalopathy,111151201,OT,,,,,,,,,111151201,1,HIV infection
11115121,111151211,1,I,,20150511,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03780,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515,N,OT,PL,ES,Efavirenz,Myocardial infarction,111151211,DE,,,,,,,,,111151211,1,HIV infection
11115125,111151251,1,I,,20150511,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03779,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515,N,OT,PL,ES,Efavirenz,Progressive multifocal leukoencephalopathy,111151251,DE,,,,,,,,,111151251,1,HIV infection
11115192,111151921,1,I,,20150511,20150515,20150515,EXP,,ES-CIPLA LTD.-2015ES03789,CIPLA,"JOANNA KRYST, PAWE? KAWALEC, ANDRZEJ PILC. EFAVIRENZ-BASED REGIMENS IN ANTIRETROVIRAL-NAIVE HIV-INFECTED PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. PLOS ONE",,,,,Y,,,20150515,N,OT,PL,ES,Efavirenz,Mycobacterium avium complex infection,111151921,OT,,,,,,,,,111151921,1,HIV infection
11115244,111152441,1,I,,20150511,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03826,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515,N,OT,US,US,Efavirenz,Toxicity to various agents,111152441,OT,,,,,,,,,111152441,1,HIV infection
11115246,111152461,1,I,,20150511,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03829,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515,N,OT,US,US,Efavirenz,Virologic failure,111152461,OT,,,,,,,,,111152461,1,HIV infection
11115284,111152841,1,I,,20150511,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03834,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE.. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515,N,OT,US,US,Efavirenz,Toxicity to various agents,111152841,OT,,,,,,,,,111152841,1,HIV infection
11115285,111152851,1,I,,20150511,20150515,20150515,EXP,,US-CIPLA LTD.-2015US03832,CIPLA,"BARTLETT.A.J, JOHNSON.J, HERRERA.G, SOSA.N, RODRIGUEZ.A, LIAO.Q, GRIFFITH.S, IRLBECK.D, SHAEFER.M.S.. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150515,N,OT,US,US,Efavirenz,Virologic failure,111152851,OT,,,,,,,,,111152851,1,HIV infection
11116909,111169092,2,F,20141031,20150601,20150515,20150605,EXP,,UG-GILEAD-2014-0123355,GILEAD,,36,YR,A,M,Y,56,KG,20150605,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Pancreatitis;Thrombocytopenia;Vomiting,111169092,HO,,,111169092,1,20140328,20141118,,,111169092,1,HIV infection
11117659,111176591,1,I,,20150511,20150518,20150518,EXP,,US-CIPLA LTD.-2015US03851,CIPLA,"JOHN A. BARTLETT, JUDY JOHNSON, GISELA HERRERA, NESTOR SOSA, ALAN RODRIGUEZ, QIMING LIAO, SANDY GRIFFITH, DAVID IRLBECK, AND MARK S. SHAEFER. LONG-TERM RESULTS OF INITIAL THERAPY WITH ABACAVIR AND LAMIVUDINE COMBINED WITH EFAVIRENZ, AMPRENAVIR/RITONAVIR, OR STAVUDINE. J ACQUIR IMMUNE DEFIC SYNDR. 2006;43:284-292",,,,,Y,,,20150518,N,OT,US,US,Efavirenz,Toxicity to various agents,111176591,OT,,,,,,,,,111176591,1,HIV infection
11119425,111194252,2,F,,20150528,20150518,20150605,EXP,,ZA-CIPLA LTD.-2015ZA03809,CIPLA,"SOGBANMU O, ADENIYI O, FUENTES Y, GOON.D. VERY EARLY VIROLOGICAL FAILURE AND DRUG RESISTANCE MUTATIONS IN A WOMAN ON ANTIRETROVIRAL THERAPY IN EASTERN CAPE, SOUTH AFRICA: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2015;9:1-9",,,,,Y,,,20150605,N,OT,ZA,ZA,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Virologic failure,111194252,OT,,,111194252,1,,201407,,,111194252,1,HIV infection
11119938,111199381,1,I,,20150508,20150518,20150518,EXP,,PHHY2015US057200,SANDOZ,"CASTILLO JJ, REAGAN JL, SIKOV WM, WINER ES. BORTEZOMIB IN COMBINATION WITH INFUSIONAL DOSE-ADJUSTED EPOCH FOR THE TREATMENT OF PLASMABLASTIC LYMPHOMA. BR-J-HAEMATOL. 2015;169(3):352-355",36,YR,,M,Y,,,20150518,N,OT,US,US,EFAVIRENZ,Neuropathy peripheral;Thrombocytopenia,111199381,OT,,,,,,,,,111199381,1,Plasmablastic lymphoma
11120006,111200061,1,I,,20150508,20150518,20150518,EXP,,PHHY2015US057199,SANDOZ,"CASTILLO JJ, REAGAN JL, SIKOV WM, WINER ES.. BORTEZOMIB IN COMBINATION WITH INFUSIONAL DOSE-ADJUSTED EPOCH FOR THE TREATMENT OF PLASMABLASTIC LYMPHOMA. BR-J-HAEMATOL. 2015;169(3):352-55.",40,YR,,M,Y,,,20150518,N,OT,US,US,EFAVIRENZ,Herpes zoster;Thrombocytopenia,111200061,OT,,,,,,,,,111200061,1,Plasmablastic lymphoma
11120376,111203761,1,I,20141002,20141014,20150518,20150518,EXP,,MW-GILEAD-2014-0118698,GILEAD,,38,YR,A,M,Y,,,20150518,N,MD,MW,MW,EFAVIRENZ,Lymph node tuberculosis,111203761,HO,,,111203761,1,20140918,20141028,,,111203761,1,HIV infection
11122358,111223581,1,I,,20150511,20150519,20150519,EXP,,ZA-CIPLA LTD.-2015ZA03852,CIPLA,"SONDERUP MW, WAINWRIGHT H, HALL P, HAIRWADZI H, WENDY C, SPEARMAN N. A CLINICOPATHOLOGICAL COHORT STUDY OF LIVER PATHOLOGY IN 301 PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNE DEFICIENCY SYNDROME. HEPATOLOGY. 2015;61:1721-1729",,,,,Y,,,20150519,N,OT,ZA,ZA,Efavirenz,Cryptococcosis,111223581,OT,,,,,,,,,111223581,1,Acquired immunodeficiency syndrome
11122723,111227231,1,I,20150311,20150430,20150519,20150519,EXP,,UG-GILEAD-2015-0153986,GILEAD,,34,YR,A,F,Y,72,KG,20150519,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,111227231,OT,,,111227231,1,20140708,20141214,,,111227231,1,HIV infection
11123708,111237082,2,F,20150429,20150522,20150519,20150605,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-031554,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20150605,N,CN,US,BR,EFAVIRENZ,Kaposi's sarcoma,111237082,HO,,,111237082,1,20150123,20150430,,,111237082,1,Acquired immunodeficiency syndrome
11123776,111237761,1,I,,20150430,20150519,20150519,PER,,US-009507513-1505USA007383,MERCK,,,,,,Y,,,20150519,N,CN,US,US,EFAVIRENZ,Drug interaction;Medication error,,,,,,,,,,,111237761,1,Antiretroviral therapy
11124149,111241491,1,I,201404,20150506,20150518,20150518,EXP,,MY2015GSK065896,VIIV,,37,YR,,M,N,,,20150515,N,OT,MY,,EFAVIRENZ,Anaemia;Lactic acidosis,111241491,OT,111241491,HP,,,,,,,111241491,1,HIV infection
11124553,111245533,3,F,20150414,20150602,20150518,20150608,EXP,,UG2015GSK065465,VIIV,,36,YR,,M,N,,,20150605,N,MD,UG,,EFAVIRENZ (EFAVIRENZ),Anaemia,111245533,HO,111245533,HP,111245533,1,20141205,20150421,,,111245533,1,HIV infection
11124871,111248711,1,I,,20150507,20150518,20150518,EXP,,MW2015GSK062927,VIIV,,54,YR,,M,N,,,20150511,N,OT,MW,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Arthropathy;Bone fragmentation;Hypersensitivity;Hypoaesthesia;Neuropathy peripheral;Osteoarthritis;Osteonecrosis;Osteosclerosis;Rash,111248711,OT,111248711,LIT,,,,,,,111248711,1,HIV infection
11128336,111283361,1,I,,20150429,20150521,20150521,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-029103,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150521,N,CN,US,US,SUSTIVA,Burning sensation;Foreign body;Product quality issue,,,,,,,,,,,111283361,1,HIV infection
11130363,111303631,1,I,,20150508,20150522,20150522,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-033975,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,,,20150522,N,OT,US,US,EFAVIRENZ,Neuropathy peripheral;Thrombocytopenia,,,,,,,,,,,111303631,1,Plasmablastic lymphoma
11132548,111325481,1,I,,20150508,20150522,20150522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-031553,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20150522,N,OT,US,US,EFAVIRENZ,Herpes zoster;Thrombocytopenia,111325481,OT,,,,,,,,,111325481,1,Plasmablastic lymphoma
11132614,111326141,1,I,,20150508,20150522,20150522,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-033976,BRISTOL MYERS SQUIBB,,66,YR,,M,Y,,,20150522,N,OT,US,US,EFAVIRENZ,Small intestinal obstruction;Thrombocytopenia,111326141,OT,,,,,,,,,111326141,1,Plasmablastic lymphoma
11139329,111393292,2,F,20150414,20150527,20150522,20150605,EXP,,FR2015GSK054104,VIIV,,64,YR,,M,N,,,20150604,N,OT,FR,,SUSTIVA,Arthralgia;Discomfort;Dizziness;Fatigue;Headache;Malaise;Myalgia;Nausea;Paraesthesia;Poor quality sleep;Pruritus,111393292,RI,111393292,HP,111393292,1,20150413,20150416,,,111393292,1,HIV infection
11142534,111425341,1,I,2010,20150520,20150527,20150527,EXP,,US-BMSGILMSD-2015-0154760,GILEAD,,36,YR,A,M,Y,,,20150527,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain neoplasm,111425341,DS,,,111425341,1,2010,,,,111425341,1,HIV infection
11146019,111460191,1,I,20150517,20150518,20150528,20150528,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK069313,GLAXOSMITHKLINE,,,,,M,Y,,,20150528,N,CN,RU,RU,Efavirenz,Depressed level of consciousness,111460191,OT,,,111460191,1,20150517,,,,111460191,1,HIV infection
11146331,111463311,1,I,200704,20150519,20150526,20150526,EXP,,IT2015GSK069958,VIIV,,36,YR,,M,N,,,20150522,N,OT,IT,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Bundle branch block left;Cardiac failure chronic;Congestive cardiomyopathy;Regurgitation;Ventricular extrasystoles,111463311,HO,111463311,HP,,,,,,,111463311,1,HIV infection
11147779,111477791,1,I,20150324,,20150528,20150528,DIR,,,,,75,YR,,M,N,69.1,KG,20150421,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Bile duct stone;Diverticulum;Drug-induced liver injury;Pancreatitis,111477791,HO,111477791,HP,111477791,1,20141001,20150324,,,111477791,1,HIV infection
11148307,111483071,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04144,CIPLA,"BM BEST, S BURCHETT, H LI,  A STEK, C HU, J WANG, E HAWKINS, M BYROADS, DH WATTS, E SMITH, CV FLETCHER. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND POSTPARTUM. HIV MEDICINE. 2015",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Dacryostenosis congenital;Foetal exposure during pregnancy,111483071,CA,,,,,,,,,,,
11148312,111483121,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04143,CIPLA,"BM BEST, S BURCHETT, H LI,  A STEK, C HU, J WANG, E HAWKINS, M BYROADS, DH WATTS, E SMITH, CV FLETCHER. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND POSTPARTUM. HIV MEDICINE. 2015",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Developmental hip dysplasia;Foetal exposure during pregnancy,111483121,CA,,,,,,,,,,,
11148313,111483131,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04145,CIPLA,"BM BEST, S BURCHETT, H LI,  A STEK, C HU, J WANG, E HAWKINS, M BYROADS, DH WATTS, E SMITH, CV FLETCHER. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND AND POSTPARTUM. HIV MEDICINE. 2015",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Congenital naevus;Foetal exposure during pregnancy,111483131,CA,,,,,,,,,,,
11148405,111484051,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04147,CIPLA,"BM BEST, S BURCHETT, H LI,  A STEK, C HU, J WANG, E HAWKINS, M BYROADS, DH WATTS, E SMITH, CV FLETCHER. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND POSTPARTUM. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Foetal exposure during pregnancy;Parvovirus infection,111484051,OT,,,,,,,,,,,
11148433,111484331,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04146,CIPLA,"BM BEST, S BURCHETT, H LI,  A STEK, C HU, J WANG, E HAWKINS, M BYROADS, DH WATTS, E SMITH, CV FLETCHER. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND POSTPARTUM. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Foetal exposure during pregnancy;Vesicoureteric reflux,111484331,OT,,,,,,,,,,,
11148439,111484391,1,I,,20150521,20150529,20150529,EXP,,US-CIPLA LTD.-2015US04130,CIPLA,"BM BEST, S BURCHETT, H LI, A STEK, C HU, J WANG ET AL. PHARMACOKINETICS OF TENOFOVIR DURING PREGNANCY AND POSTPARTUM. HIV MEDICINE. 2015;1-10",,,,,Y,,,20150529,N,OT,US,US,Efavirenz,Accessory auricle;Foetal exposure during pregnancy,111484391,CA,,,,,,,,,,,
11148863,111488631,1,I,,20150521,20150529,20150529,EXP,,US-BMSGILMSD-2015-0154933,GILEAD,,43,YR,A,F,Y,65.76,KG,20150529,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Headache;Hyperhidrosis;Malaise;Osteomyelitis bacterial;Tuberculosis,111488631,OT,,,,,,,,,111488631,1,HIV infection
11149326,111493261,1,I,20150212,20150430,20150529,20150529,EXP,,KE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-030457,BRISTOL MYERS SQUIBB,,47,YR,,F,Y,31,KG,20150529,N,CN,US,KE,EFAVIRENZ,Acute kidney injury;Death;Drug-induced liver injury;HIV wasting syndrome;Hepatitis B;Jaundice;Pulmonary tuberculosis,111493261,OT,,,111493261,1,20150121,20150415,,,111493261,1,HIV infection
11149694,111496941,1,I,,20140701,20150529,20150529,EXP,,US-ELI_LILLY_AND_COMPANY-US201503002561,ELI LILLY AND CO,,,,,,Y,,,20150528,N,MD,US,US,SUSTIVA,Amniotic band syndrome;Cardiac murmur;Cleft lip and palate;Dysmorphism;Foetal exposure during pregnancy,111496941,CA,,,,,,,,,111496941,1,Product used for unknown indication
11152013,111520131,1,I,20150522,,20150529,20150529,DIR,,,,,78,YR,,M,N,,,20150527,N,PH,US,,SUSTIVA,Death,111520131,DE,111520131,HP,111520131,1,,20150422,,,111520131,1,HIV infection
11153047,111530471,1,I,20150212,20150430,20150601,20150601,EXP,,KE-009507513-1505KEN000457,MERCK,,46,YR,,F,Y,31,KG,20150601,N,CN,US,KE,EFAVIRENZ,Acute kidney injury;Cachexia;Death;Drug-induced liver injury;Hepatitis B;Jaundice;Pulmonary tuberculosis,111530471,HO,,,111530471,1,20150204,20150415,,,111530471,1,HIV infection
11153105,111531051,1,I,,20150527,20150601,20150601,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK073606,GLAXOSMITHKLINE,"IRO MA, ET AL.. VARICELLA ZOSTER VIRUS CENTRAL NERVOUS SYSTEM IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME PRESENTING IN A CHILD.. PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2013;32;11:1283-1284",11,YR,,F,Y,,,20150601,N,OT,GB,GB,Efavirenz,Aphasia;Carotid artery occlusion;Carotid artery stenosis;Cerebral infarction;Cerebrovascular accident;Hemiplegia;Immune reconstitution inflammatory syndrome;VIIth nerve paralysis;Varicella zoster virus infection,111531051,OT,,,,,,,,,111531051,1,HIV infection WHO clinical stage III
11154945,111549451,1,I,2015,20150518,20150529,20150529,EXP,,RU2015GSK004378,VIIV,,,,,M,N,,,20150527,N,CN,RU,,EFAVIRENZ,Abdominal pain;Scleroderma;Viral load increased,111549451,OT,111549451,FGN,111549451,1,201310,,,,111549451,1,HIV infection
11154956,111549561,1,I,20150517,20150518,20150529,20150529,EXP,,RU2015GSK069313,VIIV,,,,,M,N,,,20150527,N,CN,RU,,EFAVIRENZ,Condition aggravated;Depressed level of consciousness,111549561,OT,111549561,CSM,111549561,1,20150517,,,,111549561,1,HIV infection
11154960,111549602,2,F,2014,20150609,20150529,20150617,EXP,,FR2015GSK056018,VIIV,,45,YR,,M,N,105,KG,20150616,N,MD,FR,,ATRIPLA (EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE),Blood creatinine increased;Renal failure,111549602,OT,111549602,HP,111549602,1,20141127,20150317,,,111549602,1,HIV infection
11156162,111561621,1,I,2007,20150524,20150602,20150602,EXP,,FR-AMGEN-FRASP2015052488,AMGEN,"SIMOHAMED, BELMOUAZ, MARC BAUWENS, ET. AL.. CINACALCET IN HIV HAEMODIALYSIS PATIENTS. NDT PLUS. 2008;5:379-380",24,YR,A,F,Y,,,20150602,N,OT,FR,FR,EFAVIRENZ,Drug ineffective;Drug interaction;Drug resistance;Parathyroid tumour benign,111561621,OT,,,111561621,1,200705,200712,,,111561621,1,Blood parathyroid hormone increased
11156328,111563282,2,F,20150526,20150528,20150602,20150610,EXP,,TH-GILEAD-2015-0156142,GILEAD,,55,YR,A,M,Y,63,KG,20150610,N,MD,TH,TH,EFAVIRENZ,Myocardial infarction,111563282,OT,,,111563282,1,20140721,20150214,,,111563282,1,HIV infection
11157239,111572391,1,I,,20150521,20150602,20150602,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-034202,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20150602,N,PH,US,US,SUSTIVA,Hospitalisation;Off label use,111572391,HO,,,,,,,,,111572391,1,Product used for unknown indication
11159284,111592841,1,I,200512,20150527,20150603,20150603,EXP,,IN-GLAXOSMITHKLINE-IN2015GSK074278,GLAXOSMITHKLINE,"DUTTA N, ET AL.. A CASE OF RAPID SECOND-LINE ANTI-RETROVIRAL TREATMENT FAILURE: AN ANALYSIS OF POSSIBLE CAUSES AND PREVENTIVES.. JOURNAL OF THE INDIAN ACADEMY OF CLINICAL MEDICINE. 2014;15;3-4:229-231",45,YR,,M,Y,,,20150603,N,OT,IN,IN,EFAVIRENZ,Anaemia;Drug resistance;Gastritis;Immune system disorder;Inappropriate schedule of drug administration;Pulmonary tuberculosis;Treatment failure;Underdose,111592841,OT,,,,,,,,,111592841,1,HIV infection
11164407,111644071,1,I,1996,20150528,20150604,20150604,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK075414,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20150604,N,CN,GB,GB,Efavirenz,Depression;Diarrhoea;Nephrolithiasis,111644071,OT,,,111644071,1,1996,1998,,,111644071,1,HIV infection
11166251,111662511,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04369,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Anaemia,111662511,OT,,,,,,,,,111662511,1,HIV infection
11166253,111662531,1,I,201111,20150528,20150605,20150605,EXP,,ES-CIPLA LTD.-2015ES04334,CIPLA,,,,,,Y,,,20150605,N,OT,IT,ES,Efavirenz,Abnormal dreams;Confusional state;Disturbance in attention;Drug interaction;Irritability;Sleep disorder,111662531,OT,,,111662531,1,2007,201201,,,111662531,1,HIV infection
11166967,111669671,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04391,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Adverse drug reaction,111669671,OT,,,,,,,,,111669671,1,HIV infection
11166968,111669681,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04385,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Psychiatric symptom,111669681,OT,,,,,,,,,111669681,1,HIV infection
11166969,111669691,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04400,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Hallucination,111669691,OT,,,,,,,,,111669691,1,HIV infection
11166972,111669721,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04390,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Musculoskeletal disorder,111669721,OT,,,,,,,,,111669721,1,HIV infection
11166974,111669741,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04392,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Haematotoxicity,111669741,OT,,,,,,,,,111669741,1,HIV infection
11166975,111669751,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04378,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Hallucination,111669751,OT,,,,,,,,,111669751,1,HIV infection
11166976,111669761,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04380,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Dermatitis allergic,111669761,OT,,,,,,,,,111669761,1,HIV infection
11166979,111669791,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04403,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Agitation,111669791,OT,,,,,,,,,111669791,1,HIV infection
11166980,111669801,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04377,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Deafness,111669801,OT,,,,,,,,,111669801,1,HIV infection
11168898,111688981,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04402,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150606,N,OT,ET,ET,Efavirenz,Memory impairment,111688981,OT,,,,,,,,,111688981,1,HIV infection
11168900,111689001,1,I,,20150529,20150605,20150605,EXP,,ET-CIPLA LTD.-2015ET04399,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150606,N,OT,ET,ET,Efavirenz,Psychotic disorder,111689001,OT,,,,,,,,,111689001,1,HIV infection
11169047,111690471,1,I,,20150602,20150605,20150605,EXP,,US-BMSGILMSD-2015-0156591,GILEAD,,47,YR,A,M,Y,,,20150605,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dementia,111690471,HO,,,,,,,,,111690471,1,HIV infection
11169671,111696711,1,I,,20150528,20150605,20150605,EXP,,FR-GILEAD-2015-0157176,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GATEY C, YANG C, DENIS B, FONSART J, DELAUGERRE C, DESSEAUX K, GUIONIE M, ROZENBAUM W, MOLINA J-M. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE-BASED REGIMENS IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS: A PROSPECTIVE COHORT STUDY. 53RD ICAAC MEETING, SEPT 10-13, 2013, DENVER CO USA. 2013;UNK:UNK",,,A,,Y,,,20150605,N,OT,FR,FR,EFAVIRENZ,Completed suicide,111696711,OT,,,,,,,,,111696711,1,HIV infection
11169682,111696821,1,I,,20150528,20150605,20150605,EXP,,FR-GILEAD-2015-0157177,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GATEY C, YANG C, DENIS B, FONSART J, DELAUGERRE C, DESSEAUX K, GUIONIE M, ROZENBAUM W, MOLINA J-M. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE-BASED REGIMENS IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS: A PROSPECTIVE COHORT STUDY. 53RD ICAAC MEETING, SEPT 10-13, 2013, DENVER CO USA. 2013;UNK:UNK",,,A,,Y,,,20150605,N,OT,FR,FR,EFAVIRENZ,Completed suicide,111696821,OT,,,,,,,,,111696821,1,HIV infection
11169936,111699361,1,I,,20150529,20150608,20150608,EXP,,ET-CIPLA LTD.-2015ET04398,CIPLA,"WOLDESELLASSIE M. BEZABHE, LUKE R. BEREZNICKI, LEANNE CHALMERS, PETER GEE, DESALEW M. KASSIE, MEKIDES A. BIMIREW, GREGORY PETERSON. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT STUDY FROM ETHIOPIA. DRUG SAF. 2015;1-11",,,,,Y,,,20150605,N,OT,ET,ET,Efavirenz,Hypoaesthesia,111699361,OT,,,,,,,,,111699361,1,HIV infection
11169947,111699471,1,I,200512,20150527,20150604,20150604,EXP,,IN2015GSK074278,VIIV,,45,YR,,M,N,,,20150603,N,,IN,,EFAVIRENZ (EFAVIRENZ),Anaemia;Drug resistance;Gastritis;Immune system disorder;Inappropriate schedule of drug administration;Pulmonary tuberculosis;Treatment failure;Underdose;Virologic failure,111699471,OT,111699471,HP,,,,,,,111699471,1,HIV infection
11170562,111705621,1,I,,20150527,20150604,20150604,EXP,,GB2015GSK073606,VIIV,,11,YR,,F,N,,,20150601,N,OT,GB,,EFAVIRENZ,Carotid artery occlusion;Carotid artery stenosis;Cerebral infarction;Cerebrovascular accident;Immune reconstitution inflammatory syndrome;Varicella zoster virus infection,111705621,HO,111705621,LIT,,,,,,,111705621,1,HIV infection WHO clinical stage III
11172357,111723571,1,I,,20150601,20150608,20150608,EXP,,CH-CIPLA LTD.-2015CH04426,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART-A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;165",,,,,Y,,,20150608,N,OT,CH,CH,Efavirenz,Acute kidney injury,111723571,OT,,,,,,,,,111723571,1,HIV infection
11172358,111723581,1,I,,20150601,20150608,20150608,EXP,,CH-CIPLA LTD.-2015IT04465,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART - A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;145:1-6",,,,,Y,,,20150608,N,OT,CH,CH,Efavirenz,Acute kidney injury,111723581,OT,,,,,,,,,111723581,1,HIV infection
11174166,111741661,1,I,1996,20150528,20150605,20150605,EXP,,GB2015GSK075414,VIIV,,54,YR,,M,N,,,20150604,N,MD,GB,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Depression;Diarrhoea;Nephrolithiasis,111741661,OT,111741661,HP,111741661,1,1996,1998,,,111741661,1,HIV infection
11175471,111754711,1,I,,20150601,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04445,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria,111754711,OT,,,,,,,,,111754711,1,HIV infection
11175472,111754721,1,I,,20150601,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04443,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria,111754721,OT,,,,,,,,,111754721,1,HIV infection
11175473,111754731,1,I,,20150601,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04440,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609,N,OT,IT,IT,Efavirenz,Proteinuria,111754731,OT,,,,,,,,,111754731,1,HIV infection
11175475,111754751,1,I,,20150601,20150609,20150609,EXP,,IT-CIPLA LTD.-2015IT04434,CIPLA,"VANIA GIACOMET, PILAR NANNINI, ALESSANDRA VIGANO, PAOLA ERBA, ANNARITA BENINCASO, GIORGIO BEDOGNI, DARIO CATTANEO, FELICIA STEFANIA FALVELLA, GIAN VINCENZO ZUCCOTTI. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY. CLIN DRUG INVESTIG. 2015",,,,,Y,,,20150609,N,OT,IT,IT,Efavirenz,Genetic polymorphism;Hypophosphataemia;Proteinuria;Renal failure,111754751,OT,,,,,,,,,111754751,1,HIV infection
11176991,111769911,1,I,,20150601,20150610,20150610,EXP,,CH-CIPLA LTD.-2015CH04455,CIPLA,"MARIO KURZ, FELIX BURKHALTER, MICHAEL DICKENMANN, HELMUT HOPFER, MICHAEL MAYR, LUIGIA ELZI, MANUEL BATTEGAY. ACUTE KIDNEY INJURY KDIGO STAGE 2 TO 3 IN HIV-POSITIVE PATIENTS TREATED WITH CART-A CASE SERIES OVER 11 YEARS IN A COHORT OF 1,153 PATIENTS. SWISS MEDICAL WEEKLY. 2015;145",,,,,Y,,,20150610,N,OT,CH,CH,Efavirenz,Acute kidney injury;Focal segmental glomerulosclerosis;Multiple-drug resistance,111769911,OT,,,,,,,,,111769911,1,HIV infection
11177717,111777171,1,I,20150603,,20150609,20150609,DIR,,,,,57,YR,,F,N,130,LBS,20150608,N,CN,US,,SUSTIVA,Abdominal pain;Abdominal pain upper;Constipation;Diarrhoea haemorrhagic;Faeces discoloured;Muscle spasms,,,111777171,CSM,111777171,1,20150603,20150608,,,111777171,1,Arthralgia
11183985,111839851,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04548,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Kaposi's sarcoma,111839851,OT,,,,,,,,,111839851,1,HIV infection
11183986,111839861,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04545,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Kaposi's sarcoma,111839861,OT,,,,,,,,,111839861,1,HIV infection CDC category C
11184007,111840071,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04546,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Cervix carcinoma,111840071,OT,,,,,,,,,111840071,1,HIV infection CDC category C
11184390,111843901,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04551,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Molluscum contagiosum,111843901,OT,,,,,,,,,111843901,1,HIV infection
11184393,111843931,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04623,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Urogenital disorder,111843931,OT,,,,,,,,,111843931,1,HIV infection
11184399,111843991,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04549,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Toxoplasmosis,111843991,OT,,,,,,,,,111843991,1,HIV infection
11184403,111844031,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04622,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Adverse event,111844031,OT,,,,,,,,,111844031,1,HIV infection
11184411,111844111,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04624,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Skin toxicity,111844111,OT,,,,,,,,,111844111,1,HIV infection
11184415,111844151,1,I,,20150604,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04625,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Laboratory test abnormal,111844151,OT,,,,,,,,,111844151,1,HIV infection
11185556,111855561,1,I,,20150605,20150612,20150612,EXP,,CH-GILEAD-2015-0157811,GILEAD,"BIVER E, DOCO-LECOMPTE T. EVENT: 1ST SWISS HIV COHORT STUDY METABOLIC AND AGING WORKSHOP. SLIDE PRESENTATION. 2015;UNK:UNK",57,YR,A,M,Y,,,20150612,N,OT,CH,CH,EFAVIRENZ,Osteoporosis,111855561,OT,,,111855561,1,2003,2013,,,111855561,1,HIV infection
11200772,112007721,1,I,20140917,20150610,20150618,20150618,EXP,,BW-BMSGILMSD-2015-0158227,GILEAD,,37,YR,A,F,Y,,,20150618,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,112007721,OT,,,112007721,1,20120730,,,,112007721,1,HIV infection
11202759,112027591,1,I,20150529,20150605,20150619,20150619,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038093,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20150619,N,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Decreased appetite;Malaise;Renal failure;Vomiting,112027591,OT,,,112027591,1,20131002,20140120,,,112027591,1,Kaposi's sarcoma
11203820,112038201,1,I,,20150616,20150619,20150619,EXP,,US-GILEAD-2015-0159102,GILEAD,,,,,M,Y,,,20150619,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Loss of consciousness,112038201,OT,,,,,,,,,112038201,1,HIV infection
11203983,112039831,1,I,,20150611,20150619,20150619,EXP,,MY-ABBVIE-15P-101-1409411-00,ABBVIE,,,,,M,Y,,,20150619,N,OT,COUNTRY NOT SPECIFIED,MY,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly,112039831,CA,,,,,,,,,112039831,1,Maternal exposure timing unspecified
11209004,112090041,1,I,20090424,20150608,20150622,20150622,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-040358,BRISTOL MYERS SQUIBB,,4,DEC,,M,Y,,,20150622,N,CN,US,JP,EFAVIRENZ,Platelet count decreased,112090041,DS,,,112090041,1,20010809,20080331,,,112090041,1,HIV infection
11210698,112106981,1,I,,20150609,20150622,20150622,EXP,,IT-GILEAD-2015-0158441,GILEAD,"GIACOMET V., NANNINI P., VIGANO A., ERBA P., BENINCASO A., BEDOGNI G., CATTANEO D., FALVELLA F. S., ZUCCOTTI G. V.. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY.. CLINICAL DURG INVESTIGATION. 2015;UNK:UNK",,,C,,Y,,,20150622,N,OT,IT,IT,EFAVIRENZ,Renal failure,112106981,OT,,,,,,,,,112106981,1,HIV infection
11213248,112132481,1,I,,20150609,20150623,20150623,EXP,,IT-GLAXOSMITHKLINE-IT2015088154,GLAXOSMITHKLINE,"GIACOMET V., NANNINI P., VIGANO A., ERBA P., BENINCASO A., BEDOGNI G., CATTANEO D., FALVELLA F. S., ZUCCOTTI G. V.. LONG-TERM RENAL EFFECTS OF TENOFOVIR-DISOPROXIL-FUMARATE IN VERTICALLY HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS: A 132-MONTH FOLLOW-UP STUDY.. CLINICAL DURG INVESTIGATION. 2015;UNK:UNK",,,C,,Y,,,20150623,N,OT,IT,IT,Efavirenz,Renal failure,112132481,OT,,,,,,,,,112132481,1,HIV infection
11213627,112136271,1,I,20140211,20150610,20150623,20150623,EXP,,MY-MYLANLABS-2015M1020401,MYLAN,,,,,,Y,,,20150623,N,OT,MY,MY,EFAVIRENZ,Anaemia;Dyspnoea;Lethargy,112136271,OT,,,,,,,,,112136271,1,HIV infection
11213637,112136371,1,I,20140102,20150610,20150623,20150623,EXP,,MY-MYLANLABS-2015M1020435,MYLAN,,,,,,Y,,,20150623,N,OT,MY,MY,EFAVIRENZ,Anaemia;Dizziness;Dyspnoea,112136371,OT,,,,,,,,,112136371,1,HIV infection
11216235,112162351,1,I,,20150617,20150624,20150624,EXP,,US-CIPLA LTD.-2015US05019,CIPLA,"OVERTON ET, CHAN ES, BROWN TT, TEBAS P, MCCOMSEY GA, MELBOURNE KM, NAPOLI A, HARDIN WR, RIBAUDO HJ, YIN MT. VITAMIN D AND CALCIUM ATTENUATE BONE LOSS WITH ANTIRETROVIRAL THERAPY INITIATION: A RANDOMIZED TRIAL. ANN INTERN MED. 2015;162:815-24",,,,,Y,,,20150624,N,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Nephrolithiasis,112162351,OT,,,,,,,,,112162351,1,HIV infection
11222432,112224321,1,I,201506,20150421,20150626,20150626,EXP,,US-BMSGILMSD-2015-0150261,GILEAD,,25,YR,A,F,Y,,,20150626,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Drug dose omission;Dysphonia;Hearing aid user;Hearing impaired;Malaise;Nausea,112224321,HO,,,,,,,,,112224321,1,HIV infection
11224138,112241381,1,I,,20150609,20150625,20150625,EXP,,IT2015088154,VIIV,,,,,,N,,,20150623,N,OT,IT,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Renal failure,112241381,OT,112241381,HP,,,,,,,112241381,1,HIV infection
11224618,112246181,1,I,20150614,20150615,20150625,20150625,EXP,,RU2015GSK086269,VIIV,,,,,,N,,,20150620,N,CN,RU,,STOCRIN (EFAVIRENZ),Chest pain;Chromaturia;Faeces discoloured;Pleurisy;Pulmonary tuberculosis;Pyrexia;Rash,112246181,OT,112246181,CSM,112246181,1,201502,20150601,,,112246181,1,HIV infection
11224691,112246911,1,I,2014,20150615,20150625,20150625,EXP,,B0987385A,VIIV,,,,,F,N,,,20150619,N,CN,RU,,STOCRIN (EFAVIRENZ),Anaemia;Dyspepsia;Fatigue;Feeling hot;Jaundice;Lipodystrophy acquired;Pain;Pyrexia;Red blood cell sedimentation rate increased;Yawning,112246911,OT,112246911,CSM,112246911,1,2014,,,,112246911,1,HIV infection
11224736,112247361,1,I,20140610,20150611,20150625,20150625,EXP,,B1031199A,VIIV,,32,YR,,M,N,,,20150619,N,MD,UG,,EFAVIRENZ (EFAVIRENZ) UNKNOWN,Anaemia,112247361,LT,112247361,FGN,112247361,1,20140318,20140901,,,112247361,1,HIV infection
11225710,112257101,1,I,20150312,20150409,20150629,20150629,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-024150,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20150629,N,CN,US,ZW,EFAVIRENZ,Gastroenteritis;Tuberculosis,112257101,HO,,,112257101,1,20150226,20150302,,,112257101,1,HIV infection
4196147,41961476,6,F,20040323,20060324,20040825,20150415,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12676359,BRISTOL MYERS SQUIBB,,55,YR,,F,Y,,,20150415,N,CN,US,JP,EFAVIRENZ,Ascites;Hepatic encephalopathy;Hepatitis fulminant;Immune reconstitution inflammatory syndrome,41961476,HO,,,41961476,1,20040205,20040326,,,41961476,1,HIV infection
5829241,58292412,2,F,200410,20150404,20050701,20150417,EXP,,LS-BRISTOL-MYERS SQUIBB COMPANY-13019666,BRISTOL MYERS SQUIBB,,28,YR,,M,Y,49,KG,20150417,N,OT,LS,LS,EFAVIRENZ,Anaemia;Hepatotoxicity;Immune reconstitution inflammatory syndrome;Jaundice;Tuberculosis,58292412,OT,,,58292412,1,20041007,20050114,,,58292412,1,HIV infection
6902323,69023234,4,F,20070614,20150608,20090205,20150622,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14445084,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20150622,N,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Myasthenia gravis,69023234,OT,,,69023234,1,20030124,20100119,,,69023234,1,HIV infection
7302622,730262224,24,F,,20150416,20100302,20150420,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20150420,N,CN,US,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,730262224,OT,,,,,,,,,730262224,1,HIV infection
7476212,74762123,3,F,,20150501,20100715,20150514,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-15190788,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20150514,N,CN,US,CA,SUSTIVA,Depression;Drug interaction,74762123,OT,,,,,,,,,74762123,1,Product used for unknown indication
8159073,815907313,13,F,20110814,20150615,20110927,20150619,EXP,,GB-GILEAD-2011-0044197,GILEAD,,0,DY,,M,Y,,,20150619,N,OT,GB,GB,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital teratoma;Conjunctival haemorrhage;Facial paresis;Foetal exposure during pregnancy;Respiratory distress;Ultrasound antenatal screen abnormal,815907313,CA,,,815907313,1,20100915,20110913,,,815907313,1,HIV infection
8691284,86912846,6,F,20090824,20150403,20120730,20150415,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-16789448,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20150415,N,CN,US,JP,EFAVIRENZ,Diabetes mellitus;Full blood count decreased;Hepatitis C,86912846,OT,,,86912846,1,20000901,20100711,,,86912846,1,HIV infection
8912091,89120916,6,F,20121102,20130122,20121115,20150630,EXP,,US-BMSGILMSD-2012-0064557,GILEAD,,48,YR,A,M,Y,86.62,KG,20150630,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypophosphataemia,89120916,OT,,,89120916,1,201109,20121119,,,89120916,1,HIV infection
9439605,94396056,6,F,20130725,20150521,20130805,20150528,EXP,,US-MERCK-1307USA016207,MERCK,,56,YR,,M,Y,72.8,KG,20150528,N,OT,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Neutropenia;Overdose,94396056,OT,,,94396056,1,20130502,20140313,,,94396056,1,Hepatitis C
9658001,96580013,3,F,20131006,20150511,20131030,20150520,EXP,,BR-GILEAD-2013-0086280,GILEAD,,33,YR,A,M,Y,79,KG,20150520,N,MD,BR,BR,EFAVIRENZ,Arthritis reactive,96580013,HO,,,96580013,1,20120924,,,,96580013,1,HIV infection
9667907,96679073,3,F,20130917,20150504,20131104,20150507,EXP,,UG-009507513-1311UGA000967,MERCK,,44,YR,,M,Y,,,20150507,N,CN,US,UG,EFAVIRENZ,Bronchopneumonia;Cryptosporidiosis infection;Death,96679073,LT,,,96679073,1,20130902,20130904,,,96679073,1,HIV infection
9731283,97312832,2,F,20131010,20150602,20131203,20150615,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19873165,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,,,20150615,N,CN,US,UG,EFAVIRENZ,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood bilirubin increased;Hepatomegaly;Nausea;Pyrexia;Vomiting,97312832,LT,,,97312832,1,20131002,20131021,,,97312832,1,HIV infection
9860022,98600225,5,F,,20150421,20140131,20150429,EXP,,GB-GILEAD-2014-0093213,GILEAD,,,,,F,Y,,,20150429,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cytomegalovirus test positive;Polyhydramnios;Trisomy 21,98600225,OT,,,98600225,1,20130818,20140512,,,98600225,1,HIV infection
